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Bedaquiline (BDQ) is the latest Tuberculosis (TB) drug belonging to the 
diarylquinolines class of compounds. Several genetic, biochemical, and modeling 
studies have previously shown that the membrane-embedded oligomeric subunit – 
c ring, of the mycobacterial ATP synthase enzyme complex, is the target of this 
drug. However, our collaborators have recently shown through NMR and 
tryptophan fluorescence spectroscopy that BDQ also interacts with specific amino 
acid residues of the ε subunit. From these structural-biology and biochemical data, 
we hypothesized that the drug BDQ also targets the ε subunit of the enzyme 
complex, in addition to the c subunit. In this PhD project, our main aim was to 
carry out experiments which could provide the first genetic evidence for a second 
binding site for BDQ. To test our hypothesis, our approach was to perform point 
mutations in the atpC gene coding for ε subunit of mycobacterial ATP synthase at 
specific amino acid residues, and observe the effect of these mutations on the 
BDQ susceptibility of the bacteria. These mutations would be performed using the 
recombineering (Recombination-mediated-genetic-engineering) technique. 
 
 
We began this project with the optimization of the recombineering technique. 
During this optimization, as described in chapter 3, we used a range of different 











and during this process also created a previously known viable BDQ resistant 
mutant I66M (mutation in c subunit), and confirmed its resistance-phenotype. 
 
 
Next, we created two desired point mutations W16A (this unique tryptophan 
16 of ε (Epsilon) subunit is one of the key residues involved in the drug binding) 
and R37G in the atpC gene as discussed in chapter 4. After confirming the 
mutations by sequencing, the new mutant strains M. smegmatis atpC
W16A
 and M. 
smegmatis atpC
R37G
 were microbiologically characterized. The mutants 
displayed similar growth behavior as that of the wild type, suggesting that these 
mutations did not affect bacterial growth. Interestingly, when they were subjected 
to BDQ susceptibility test by determining the MIC, the M. smegmatis atpC
W16A
 
showed a 5-fold-increased sensitivity to BDQ compared to that of the wild type 
(M. smegmatis atpC
R37G
 behaved similar to wild type). This hypersensitivity of 
the bacterium could be due to the replacement of the bulky tryptophan with a 
smaller alanine, which provides more space for a stronger binding of the drug to 
the ε subunit. Next, complementation experiments were carried out, to confirm 
that the point mutation W16A was indeed responsible for this hypersensitivity 
phenotype. As an independent line of evidence to confirm the binding of BDQ to 
the ε subunit, an overexpression experiment was also performed, results of which 












In addition to exploring the mechanism of action of BDQ, another objective of 
this project was to understand the roles of the c-terminal amino acid residues of the 
 
ε subunit of mycobacterial ATP synthase complex in ATP synthesis and hydrolysis 
which is described in chapter 5. We created 2 mutations in the atpC gene where the 
 
ε-c-terminal was truncated to different extents by introducing STOP codons. 
Inverted membrane vesicles of these mutants were subjected to ATP (Adenosine-
Tri-Phosphate) synthesis and hydrolysis assays. From the results of these 
biochemical assay it was evident that the C-terminal domain of the ε subunit has 




In conclusion, through this PhD project, we provide for the first time, genetic 
evidence of a second binding site of the latest TB drug Bedaquiline involving 
subunit ε of the mycobacterial F-ATP synthase. This information might be crucial 
for the discovery of the next generation of diarylquinolines. Also, we gathered 
important insights on role of C-terminal domain of ε subunit which could open 
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1.1 Tuberculosis: The persistent evil 
 
 
Tuberculosis (TB), a disease caused by the bacterium Mycobacterium 
tuberculosis (MTB) has been ravaging humankind since antiquity. The term 
 
“tuberculosis” was coined by Johann Lukas Schönle in 1839, from the Latin word 
“tuberculum,” which refers to “swelling or bump” [1]. But it was only in 1882 
when Dr. Robert Koch discovered the tubercle bacillus, for which he was later 
awarded with Nobel Prize in 1905 [2], that the term “Tuberculosis” began to be 
commonly used for the disease. Previously, this disease had been referred to by 
several other names like ‘consumption’, (because it would “consume” the patient 
by its severe weight loss symptoms), ‘phthisis pulmonaris’ and ‘the white plague’ 
[3]. Spinal tuberculosis, also known as ‘Pott’s disease’, has been detected in 
Egyptian mummies by archaeologists [4][5]. 
 
TB can have various manifestations where the meninges, pleura, bones or skin 
etc. could be affected (Extra-pulmonary TB), but it is the pulmonary TB which is the 
most notorious of them all, where the lungs are affected [6]. Even today, in spite of 
all the advancement in screening, diagnosis and treatment techniques, it continues to 
be a global health challenge [7] being the deadliest of all infectious diseases caused 
by bacteria [8]. More than one-third of the current world population is infected with 
Mycobacterium tuberculosis [9]. Most of these infections cause latent TB which 
might develop into active TB at a later stage. Recently, co-infection with Human 









Saharan Africa) [10] and emergence of Multi Drug Resistant (MDR) and 
Extensive Drug Resistant (XDR) strains [11] have worsened the scenario globally 
[12][13][14][15]. WHO has come up with a vision of ‘zero-TB world’ aiming to 
alleviate the global healthcare system including the affected third world countries, 
with better and safer drugs and vaccines [16]. 
 
The tubercle bacilli are transmitted through aerosol droplets from an infected 
individual when she coughs or sneezes [17]. When inhaled by a new host, some 
bacilli are able to invade the respiratory tract, finally getting phagocytosed by 
alveolar macrophages [18]. However, MTB has developed several strategies for 
intracellular survival in these scavenging cells. After phagocytosis by 
macrophages, these bacilli reside inside the phagosomes which they prevent from 
maturing and, as a result, inhibits their fusion with acidic and hydrolase-rich 
lysosomes [19]. These infected macrophage cells trigger a pro-inflammatory 
response, employing more cells from neighboring blood vessels [20]. 
Accumulation of these cells initiate the formation of the histo-pathological 
hallmark of TB-granulomas. At this stage, the disease could be contained, 
depending upon the immune status of the host [21]. If containment fails, it leads 
to necrosis and cavitation [19], spilling bacilli in the airway of the infected host, 
and thus sustaining the infection cycle. 
 
The current TB treatment which comprises of a cocktail of first-line antibiotics 









consisting of an initial phase of two months with these four drugs and a continuation 
phase of four months with two drugs, Rifampicin and Isoniazid [22] [23]. This long 
treatment time inevitably results in poor patient compliance. Consequence of that is 
the emergence of MDR and XDR TB strains [24]. The latency of TB infection and 
the long duration of TB treatment is due to the capability of mycobacteria to survive 
in a non-replicating hypo metabolic state in the host [25]. In this state the bacteria can 
not only persist within the host for a prolonged period, but they also exhibit 
phenotypic drug resistance. The transition of the bacteria from the replicating to 
dormant stage is triggered by adverse conditions such as low oxygen levels, nutrient 
deprivation and presence of toxic gases [26] [27] [28] [29] [30] . In the dormant state, 
the thickness of the bacterial cell wall increases, nucleic acid and protein synthesis 
decreases while lipid metabolism becomes the main source of energy [31]. These 
alterations in the major metabolic pathways results in decreased sensitivity of these 
non-replicating bacteria to the current anti-TB drugs. 
 
In spite of the dormant phenotype, these bacteria still require a basal level of 
energy to maintain viability, and any further depletion in the ATP level would be 
lethal [32]. 
 
The essentiality of the respiratory chain components in both replicating and 
non-replicating bacteria could therefore be exploited by drugs which would target 












Identification of new drug candidates which target the respiratory chain – 
Bedaquiline targeting the F1Fo ATP synthase and Q203 targeting the cytochrome 
bc1 complex [33] [34] – are examples which support this idea. Hence, the 
mycobacterial respiratory chain especially the F-ATP synthase has recently 
attracted attention emphasizing the need of the more detailed understanding of its 
structure and function. 
 
 
1.2 Respiration and ATP synthase 
 
In bacteria, ATP could be generated by substrate level phosphorylation and/or 
by ATP synthase. In some bacteria like B. subtilis, the ATP produced by 
substrate level phosphorylation is sufficient for their growth. In contrast, in 
 
Mycobacterium sp. the production of ATP mediated by ATP synthase is 
essential for its optimal growth [35]. 
 
 
1.2.1. Electron transport chain 
 
 
The Electron Transport Chain (ETC) comprise of a series of proteins responsible 
for transfer of electrons through the chain from electron donors to acceptors via redox 
reactions, accompanied with transfer of protons across the membrane [36]. In 
eukaryotes, they are present in the inner mitochondrial membrane where they are the 













present in the thylakoid membrane of chloroplasts in eukaryotes which perform 
 





















As depicted in Fig. 1.2 [31] below, electron donors like NDH-2 (yellow) or 
 




















Fig. 1.2: Another schematic representation of the mycobacterial respiratory chain with colour coded 
 















MKH2 can be oxidized by either Cytochrome bc (dark green)/cytochrome aa3 
(pink) super-complex or by the cytochrome bd oxidase (light green) to be 
transferred to the final electron acceptor, molecular oxygen. Transfer of electrons 
through these carriers is accompanied by transfer of protons across the membrane, 
resulting in electrochemical proton gradient. The proton motive force thus 
generated is used by ATP synthase (light blue) to produce Adenosine Tri 
Phosphate (ATP) from Adenosine Di Phosphate (ADP) and inorganic phosphate 
(Pi). The nitrate reductase and transporter system is shaded in brown. In this 
figure, the type-I proton-translocating NADH dehydrogenase (NDH-1), which is 
not essential for the mycobacterial growth, has not been shown [31]. 
 
 
1.2.2 Mycobacterial F1FO ATP synthase 
 
 
ATP syntheses are multi-subunit-protein complexes which are located in the 
energy-transducing membranes of bacteria, chloroplasts and mitochondria [40]. 
These nano-biological-machines use the transmembrane proton motive force as 
the source of energy to drive a mechanical rotary system which in turn results in 




















































Fig. 1.3: The F1F0 ATPase of M. tuberculosis consists of a membrane-embedded FO domain and a 
cytosolic F1 part. Protons (H
+
) are pumped from the periplasm into the cytoplasm causing the c 
ring to rotate along with subunits γ and ε. Interaction of the central stalk with the hexameric 
headpiece of the F1 part (α3, β3 assembly) leads to conformational changes within the catalytic β 
subunits, which results in the synthesis of ATP from ADP+Pi. Source: Modified from [41]. 
 
 
In eukaryotes and prokaryotes most of the ATP is synthesized by F1FO -ATPase 
(F-ATPase). The archaeal A1AO-ATPase and vacuolar V1VO-ATPase are close 
relatives of the F-ATPase differing slightly in the subunit composition [42]. All the 
three types of ATPases consist of a mosaic of globular structural units, which play 













same irrespective of their source, comprising of three different functional 
 
compartments [43] [44], given as follows: 
 
1) A membrane bound domain Ao/Fo/Vo containing the ion channel 
 
2) A spherical cytoplasmic domain A1/F1/V1 containing the catalytic sites 
 
3) A central stalk connecting the two above domains 
 
The mycobacterial F1FO-ATPase (Fig. 1.3) is made up of a water soluble F1 
domain (comprising of 3 alternating α and β subunits; one each γ, δ and ε subunits) 
and a membrane-embedded FO domain (comprising of one each of a, b and b’ 
subunits; and 9-12 sub-subunits of ‘c’ which form a ring like oligomeric structure). 
 
This catalytic α3β3-headpiece is connected to the ion-pumping FO part by the two 
rotating central stalk subunits γ and ε, as well as the peripheral stalk subunits b, b’ 
and δ. Protons (H
+
) are pumped via subunit ‘a’ through the ring structure composed 
of the oligomeric c subunits (brown) from periplasm into the cytoplasm of the cell 
[44]. This triggers rotation of the c ring along with the central stalk subunits γ (deep 
blue) and ε (violet). Subunit γ of the central stalk connects the FO domain with the 
catalytic headpiece of the F1 part, comprising of a hexameric α3 (red):β3(yellow) 
assembly. This event in turn leads to conformational changes within the β subunits 
 
(the actual catalytic site where ATP is formed from ADP and Pi) such that during 
every cycle each of them adopts sequentially three different nucleotide-binding 













The ADP+Pi are bound loosely but closely in the ‘loose’ conformation. In the 
 
‘tight’ conformation the ligands bind tightly resulting in the catalysis of the 
reaction to form ATP from ADP and Pi. The third conformation is ‘open’ and in 
this state there is low affinity for nucleotide binding, therefore resulting in release 
of ATP into the cytoplasm of the cell [46]. The two separate events of proton 
pumping by the F0 domain and ATP synthesis by F1 domain are coupled through 
the central stalk subunits γ and ε [47]. 
 
The ATP operon comprise of essential genes coding for the different subunits 
in F1Fo ATP synthase enzyme complex [48] (Fig. 1.4). The genes relevant to this 
project are the atpC gene which encodes for the epsilon subunit and the atpE gene 











Fig. 1.4: Schematic representation of the genes in ATP operon and their respective subunits they 
 




1.3 Bedaquiline: A new hope? 
 
Bedaquiline is the latest anti-TB drug with a novel mechanism of action, 
 














inhibiting the mycobacterial ATP synthase, emphasizes that targeting the energy 







Bedaquiline (BDQ), formerly known as TMC207 (Tibotec Medicinal 
Compound 207), R207910 or ‘J’-compound is the latest anti-TB drug to be 
approved after a long gap of 40 years, the last being Rifampicin [49] [50] [51] 
[52] [53]. It was discovered by a team of scientists led by Koen Andries at 
Johnson & Johnson Pvt. Ltd. (J&J) via a mass screening project of more than 


















BDQ is a novel diarylquinoline [56] which came in focus for the first time in 
2004 as a potential candidate for treatment of MDR-TB at the Inter-science 
Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting [57] 










on December 2012 to this drug as a part of combination therapy for the treatment 
of MDR-TB patients when no other alternative drug is available and had the 
potential to fulfill a so far unmet medical need [59] [60]. 
 
Its chemical name is 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-
2-naphthalen-1-yl-1-phenyl-butan-2-ol; the molecular formula is C32H31BrN2O2 
 





1.3.2 Pharmacological properties of BDQ 
 
 
Pharmacokinetic properties: With an oral dose of 400 mg/day, the drug 
reaches the maximum plasma concentration with a tmax of 4 hours and cmax 
of 5.5 mg/l [15]. BDQ is highly protein-bound, and is metabolized via the 
cytochrome P450 (CYP) system. Therefore, it’s co-administration with 
rifampicin, which is a potent inducer of CYP3A4 leads to a 50% reduction 
in bedaquiline concentrations [61]. BDQ is very hydrophobic (clogP ~7.3) 
[62] [63]. The mean terminal half-life of BDQ and its major metabolite 
(M2), which is four to six times less active in terms of antimycobacterial 
potency, is around 5.5 months [64] [65]. 
 
Pharmacodynamic properties: According to in-vitro studies, BDQ is potent 
against both drug-sensitive (DS) and drug-resistant (DR) strains of MTB with 











[54]. The drug has strong inhibitory effect against most of the non-tubercular 
mycobacteria (NTMs) e.g. M. abscessus, M. avium, M. intracellulare and M. 
ulcerans [66] [67] . Exposure to BDQ triggers a metabolic remodeling in 
mycobacteria, thereby enabling transient bacterial survival [68] due to which 
BDQ has a delayed onset of anti-mycobacterial activity from around Day 4. At 
any given time point in a cell there is a cellular ATP pool present which would 
allow the bacteria to survive for some time. 
 
Pre-clinical studies: BDQ was shown to have a better bactericidal activity 
than Rifampicin and Isoniazid by more than 1 log unit in mice model [54] 
 
[69]. Studies in murine model showed that treatment with BDQ regimen for 
four months was equally effective as the treatment with standard regimen for 
six months. It was also concluded that the duration of TB treatment could be 
reduced by adding BDQ in the standard regimen or substituting it with 




Clinical studies: Studies have shown that sputum conversion time could be 
significantly reduced compared to placebo by the addition of BDQ to the 
standard treatment regimen (Rates of conversion to a negative culture was 
48% in the BDQ group while only 9% in the placebo group) [34]. It was found 













1.3.3 Adverse effects and drug interaction 
 
 
Unfortunately, it has been reported that BDQ disturbs heart and liver function. 
Prolongation of QT interval, hepatotoxicity, drug interactions with CYP3A4 
inducers and inhibitors were observed in patients after this drug intake [73]. Other 
common adverse reactions observed more frequently in BDQ treatment group 
than placebo during was: nausea, arthralgia, headache, hemoptysis, chest pain, 
anorexia, increased transaminases, rash and increased blood amylase. Drug-drug 
interactions with lopinavir and efavirenz (used in the treatment of HIV), 
ketoconazole, as well as other drugs used in the treatment of MDR-TB like 
moxifloxacin, clofazimine have also been observed [74] [75]. Therefore, BDQ if 
at all used for TB treatment, can be used only under very specific conditions 




1.3.4 Mechanism of action studies 
 
 
Compared to other anti-TB drugs, BDQ has a novel and unique mechanism of 
action – it targets ATP synthase, an essential enzyme of mycobacterial energy 
metabolism. Till date, numerous genetic, biochemical and computational studies have 
been performed regarding the mechanism of action (MOA) of BDQ. Although more 













previous studies (as discussed in details below) have concluded that the BDQ 
binds to the c-ring of the ATP synthase enzyme and inhibits ATP synthesis. 
 
Since the mechanism of action of BDQ is of primary focus in this project, few 





1.3.4.1 Genetic studies 
 
 
Early in 2005 Koen Andries et al. [54] did some preliminary mechanism of 





). By comparative analysis of the genome sequences, they 
found point mutations A63P for M. tuberculosis and D32V for M. smegmatis (a 
surrogate model for MTB often used microbiological experiments) in the atpE 
gene that codes for the membrane spanning c ring subunit. 
 
In another study in 2006 [77], the atpE gene was sequenced from in-vitro 
mutants resistant to the drug. They found the previously reported [54] mutation 
A63P and a new mutation I66M in M. tuberculosis. It was also revealed in this 
study that the genetic region considered responsible for resistance to BDQ is 
conserved amongst different mycobacterial species except M. xenopi, which had a 













Whereas in [78], the authors characterized the development of resistance to 
BDQ. Out of 97 resistant mutants isolated, they sequenced the atpE gene 
(previously reported to be involved in BDQ resistance) for 53 of them. Out of 
these 53, 15 (28%) had five different point mutations in the atpE gene. No atpE 
mutations were found for the remaining 38 mutants. Out of these 38 mutants, for 
3 of them, the entire FO and F1 ATP synthase operon was sequenced, still 
revealing no mutations. This study concluded that there could be some other 
alternative resistance mechanism which needs to be explored further. 
 
In 2011, Segala et al. [79] revealed some novel mutations in the ATP synthase 
enzyme complex of MTB related to the resistance to BDQ. In-vitro resistance 
mutants were selected from M. tuberculosis and different atypical mycobacteria. Six 
specific mutations, I66M, L59V, D28A, D28G, A63P, and E61D were reported in 
subunit c (Table 1.1). The levels of resistance and the increase in the MIC for BDQ 
for each of these individual mutants were studied. The table below shows the 
characteristics (genotypic and phenotypic) of the BDQ resistant mutants. These 
mutants were from 2 reference strains – M. tuberculosis H37Rv and M. smegmatis 
mc
2
155; and 5 clinical strains – M. tuberculosis D, LQ and P, M. fortuitum B and 



















Table 1.1: The genotypic and phenotypic characteristics of the resistant mutants obtained in the 
 



















A recent study from 2014 [80], reported that Rv0678 was a candidate gene 
responsible for non-target based resistance to BDQ. They also reported cross-
resistance of BDQ to clofazimine (CFZ) due to mutations in Rv0678, a 
transcriptional repressor of the genes encoding the MmpS5-MmpL5 efflux pump. 
 
 
1.3.4.2 Biochemical studies 
 
 
Resistance to antibiotics by the bacteria could be possible by different 
mechanisms, such as, preventing the activation of the pro-drug, adapting to alternate 
metabolic pathway, inactivating the drug, modifying the target etc. [81]. Therefore, 
resistance mutations could also be found in some other genes apart from the target 
gene. For example, resistance mutations for the drug isoniazid, were not only 
restricted to the target gene inhA but also other genes like katG – the gene that 










BDQ were identified in the atpE gene, the drug target still had to be validated 
through other methods. 
 
To confirm that the drug BDQ interferes with energy metabolism of MTB by 
affecting its ability to synthesize ATP, cellular ATP was measured in presence of the 
drug [83]. Incubation with BDQ resulted in a decrease in the level of ATP in a dose 





 mutants the drug did not have any significant effect on the ATP level. BDQ 
strongly inhibited ATP synthesis activity in membrane vesicles of wildtype 
 
M. smegmatis (IC50 2.5nM), but not in the mutant atpE
D32V
. Binding studies were 
also performed [83], in which a strong binding response was observed upon 
infusion of purified wild-type subunit c onto the chip as compared to the mutant 
atpE
A63P
 subunit c. 
 
Another study [84] also involved biochemical assays and binding studies to 
characterize the binding of BDQ to the mycobacterial ATP synthase. They 
showed that the drug is not involved in competing with the protons for the same 
binding site. It was proposed that BDQ mimics key residues in the proton transfer 
chain and inhibits rotation of the c ring during catalysis. 
 
A recent study [85] which involved measuring the oxygen conversion rates in 
inverted membrane vesicles, proposed that the drug binds to the a-c subunit 














1.3.4.3 Computational studies 
 
One of the first computational model studies [86] involved creating a 
homology model which had a binding site for diarylquinoline class of molecules 
at the interface of subunit a and subunit c. With a detailed analysis of this model it 
was found that the BDQ binding pocket was made up of four helices of three 
subunit c and two helices of subunit a. They proposed that, BDQ interacts with 
Glu-61 amino acid residue of subunit c by mimicking the conserved Arg-186 






















Fig. 1.6: Homology model showing Position of Arg-186 in its folded geometry, opening a binding 
region towards Glu-61. The blue surface indicates the a-subunit, the pink surface indicates the c-
subunits. Source: [86]. 
 
 
Another study of molecular modelling and docking [87] of Diarylquinolones in 









N,N dimethyl moieties may interact with the crucial residues R186 (a subunit) 
and E61 (c subunit) when the binding occurs. 
 
A recent research article [88] reported for the first time the X-ray crystal 
structure of the mycobacterial c ring with bound BDQ (Fig. 1.7 & 1.8). The 
structure supported with other functional assays, showed that BDQ has numerous 
specific interactions with the rotor c ring, covering all its ionic binding sites, 






















Fig. 1.7: 2D plot of the BDQ and c-ring interactions. Many van der Waals (VdW) interactions and 
two hydrogen (H) bonds were found to contribute directly to the highly specific binding of BDQ 






































Fig. 1.8: Cartoon representation of BDQ-free (green) and BDQ-bound (blue) M. phlei c-ring 
structures and start and end states of the drug binding process. BDQ induces a conformational 
change in F69 to avoid steric clashes. Red arrows indicate a movement of F69, which provides 
hydrophobic platform for BDQ binding. Source: [88]. 
 
1.3.4.4 New proposed binding target 
 
 
As understood from all these previous studies on the mechanism of action of 
BDQ – genetic, biochemical or computational, it is quite clear that all of them 
conclude that subunit c is the main target of BDQ. Some studies proposed that it is 
rather the interface of subunit a and subunit c which is involved in the drug binding. 
 
A recent study [89] was conducted by our project collaborators from Nanyang 
Technological University (NTU), Singapore. The findings from this study forms the 
foundation of this PhD thesis. Those shall be discussed in more detail below. In all 
ATP synthase enzymes, the NTD of the ε subunit interacts with the γ subunit and is 
connected to the rotating oligomeric c ring directly. Since from previous studies BDQ 












it also interact with the ε subunit? To demonstrate the ε-BDQ interaction, Nuclear 
Magnetic Resonance – titration experiments were conducted. The HSQC 
spectrum of the 
15N labeled Mt ε (ε protein from MTB) being titrated against 
BDQ initially showed seven peaks (5, 9, 15, 16, 18, 24 and 105) getting distorted 
at molar ratio 1:1 (Fig. 1.9). At molar ratio 1:2, further dislocation of the peaks 
was observed with many peaks disappearing. Changes in the resonance upon the 
addition of BDQ, in the peak number 105 which was identified as Tryptophan 




















Fig. 1.9: HSQC spectra of Mtε in presence (green) and the absence (red) of BDQ. The peaks 
(representing different amino acid residues, for example, peak number 105 is for tryptophan at 




Since only the tryptophan (W16) residue had a shift in the HSQC spectra in the 
 












tryptophan fluorescence spectroscopy was later used to confirm this binding. The 
binding of BDQ to Mtε was found to have a dissociation constant of 19.1 μM. A new 
model for the interaction of BDQ molecule with the ε and c subunit was proposed 
(Fig. 1.10). The important amino acid residues located in the interface of 
 
ε and c subunit were identified - W16 of ε subunit and F50 of c subunit. This model 
showed that the BDQ molecule forms a ‘wedge’ between the ε and c subunits by 
interacting with these 2 specific amino acids. It was also predicted that other amino 
acids in ε subunit which were within 5 Å of the bound BDQ molecule (R37 and T19) 



























Fig. 1.10: A probable model representing the interaction between BDQ molecule (green) with the c-
ring (beige) and ε subunit (blue). The model shows important M. tuberculosis amino acid residues, that 
















To summarize the findings from this part of the study, a novel model of BDQ 
mechanism of action was proposed, in which the drug molecule was shown to 
interact not only with the already known c subunit, but also the ε subunit at 
specific amino acid residues. 
 
Now the question is, could this be confirmed ‘in-vivo’ i.e., in intact bacterial 
cells? In this PhD project, we employed a genetic approach to answer this question. 





1.4 Subunit epsilon of F1F0 ATP synthase in mycobacteria 
 
 
As mentioned before the mycobacterial ATP synthase is made of a water 
soluble F1 domain and a membrane-embedded Fo domain. The catalytic α3β3 
headpiece of the F1 domain is connected to the ion-pumping F1 rotor via the 
central stalk of γ and ε, and peripheral stalk b, b’ and δ [90]. 
 
In bacteria and plants, the subunit ε, which has a crucial role in translocation of 
protons, comprises of a N-Terminal Domain (NTD) β barrel and C-terminal domain 
 
(CTD) α-helices [91] [92] [93]. As shown previously [94] [95], the α-helices of 











‘compact state’ or could be in the ‘extended state’. In the extended state the second 
helix of ε-CTD interacts with α, β and γ [96] and its terminal residues of CTD bends 
around γ, causing enzyme inhibition. From the recent solution structure of the MTB 
ε subunit solved by our collaborators (unpublished data), it was shown that the 
 
MtεCTD is oriented in the opposite direction compared to most other bacilli like 
E. coli εCTD. Importantly, amino acids A119 and I120 of the very C-terminus are 
oriented towards the NTD, forming a domain-domain interface between the NTD 
and CTD via the NTD residues D47, D48, A49 and A64. The NTD on the other 
hand has a direct contact with the helix-loop-helix structure of the ion-pumping c-
ring. The ε subunit is known to play an important role in regulation of ATP 
synthesis and hydrolysis due to its coupling activity [89]. However, the factors 
and exact mechanism of such regulation are yet to be identified. In E. coli, it has 
been suggested that that the ϵCTD has distinct regulatory interactions with F1 
when rotary catalysis operates in opposite directions for the hydrolysis or 
synthesis of ATP [97]. Interestingly, the ε-CTD of MTB is shorter compared to 
other bacteria like E. coli and B. subtilis. 
 
Our collaborators at NTU, have employed a combined approach of NMR 
spectroscopy, X-ray crystallography and molecular docking studies to describe the 
first NMR structure of ε subunit of MTB revealing more information on its possible 
roles in coupling (Unpublished data G. Grüber). As a complementary approach to 










studies to find out additional information on the same. Findings from such studies 
 





1.5 Recombineering used as a tool for genetic manipulations in mycobacteria. 
 
 
In-vivo genetic manipulation in mycobacterial species is considered highly 
challenging because of its inefficiency in DNA uptake and high rate of 
illegitimate recombination relative to homologous DNA exchange [98] [99] [100]. 
A new simpler technique has been developed known as ‘recombineering’ which 
has removed the existing obstacles. Recombineering stands for recombination-
mediated-genetic-engineering. This technique was first developed in E. coli and 
later adapted to other bacteria including M. tuberculosis [101] [102]. 
 
Recombineering scores some crucial advantages when compared to classical 
genetic engineering approaches as compared in fig. 1.11. The latter is based on 
restriction digestion of the specific DNA and a cloning plasmid with the same set 
of restriction enzymes, and joining them together by ligation reaction. The 
plasmid, which now contains the desired DNA sequence, is transformed into 
electrocompetent bacteria. The plasmids amplify inside the bacterial cells with 











































Fig. 1.11: Comparison of the steps involved in classical genetic engineering and recombineering to 
 
generate a recombinant cassette in Bacterial artificial chromosome (BAC) recombinant. 
 
 
Once isolated, these plasmids can be transformed into the bacteria with the 
Bacterial artificial chromosome (BAC) to finally introduce the cloned DNA 
fragment into the BAC by homologous recombination [103]. The primary 
disadvantage of this procedure is the involvement of multiple in vitro cloning 
steps. It becomes challenging to find unique restriction sites when the DNA 
fragment size increases resulting in frequent failures. 
 
In contrast, recombineering does not depend on any restriction enzyme 
digestion and therefore has no DNA fragment size limitations. The principle 
involves to PCR-amplify a target gene, using primers that consist of sequences 
homologous to the cloning site of the BAC at their 5’ end. So, the target gene 
flanked by sequences homologous to the cloning site is amplified. These PCR 





products and BAC are then transformed into electrocompetent cells, where the target 
gene is finally introduced into the BAC by homologous recombination. The 
frequency of homologous recombination is greatly enhanced by activity of phage-
derived recombination enzymes. Electrocompetent cells are previously transformed 
with recombineering plasmid that contains genes expressing these recombination 
enzymes. Recombineering is not only useful for cloning experiments but can also be 
exploited in various ways, like introducing point mutations, insertions or generating 
deletion mutants [104] [105]. For mycobacteria, the recombination system comprise 
of the gene products 60 (gp60) and 61 (gp61), which originate from the phage Che9c 
[102]. Che9c gp60 is an exonuclease and its activity depends on double-stranded 
(ds)DNA ends. Che9c gp61 is a member of the superfamily of single-stranded 
(ss)DNA annealing proteins (SSAP) and exhibits recombinase activity by binding ss 
DNA and anneal homologous DNA. The recombineering plasmid pJV53 expresses 
gp60 and gp61 (used for double-stranded recombineering), whereas pJV62 only 
expresses gp61 (used for single-stranded recombineering). For introducing a point 
mutation by single stranded recombineering, a 70 nucleotide (nt) ssDNA 
oligonucleotide is designed with the desired point mutation (red asterisk) in the 
middle. In this case, two different oligonucleotides can be designed - one which 
anneals to the leading or one which anneals to the lagging strand during DNA 






































Fig 1.12: Schematic flowchart representing the principle of creating a point mutation (ATA  
GTA) using ss-recombineering. Electrocompetent wildtype M. smegamatis cells are transformed 
with recombineering plasmid pJV62. This plasmid codes for the gp61 or recombinase which 
facilititates homologous recombination and is under the acetamidase promoter. Next ss-
oligonucleotide carrying the desired mutation is introduced by electroporation, accompanied with 
a co-transformation plasmid. Recombinase recognize the ss-DNA, bind to them and facilitate 




The principle for double stranded recombineering is the same except, in this 
case recombineering plasmid used is pJV53 because here both the recombinase 
(gp61) as well as exonuclease (gp60) activity are required. The ds oligonucleotide 
carrying the mutation used in ds recombineering should be slightly longer than 
those used for ss recombineering, around 200 bp. In both the recombineering 
plasmids pJV62 and pJV53 the recombineering enzymes are under the control of 










In this PhD project, for gene deletion or truncation, principle of point mutation 
has been followed, where a STOP codon is inserted at the desired location. 
 
 
1.6 Goals of this project 
 
 
We live in the era of an urgent need for new TB drugs. Emergence of 
antibacterial drug resistance to the 1st and 2nd line TB drugs and a long gap in the 
TB drug discovery pipeline for almost forty years was a major concern in global 
health. Discovery of the drug BDQ in the last decade was like a ray of new hope 
to alleviate the scenario. But as the saying goes, ‘every rose has its thorns’, so 
does BDQ. Some of BDQ’s adverse effects and drug interaction (as discussed 
above) impeded its journey in attaining the full potential as the foremost TB drug. 
 
Therefore, it was granted an ‘accelerated approval’ as a part of combination 
therapy for MDR-TB patients, only when all other alternative drug options failed. 
So, can this obstacle not be overcome? 
 
The answer to this problem could be lying in the mechanism of action of the 
drug. Most of the studies till date as reviewed above have concluded that the 
membrane embedded c-ring in the mycobacterial ATP synthase is the main target of 
BDQ. But such drugs which target a membrane embedded protein, would have to 
dissolve through the membrane. To do that, these drugs should be lipophilic in 












of the octanol/water partition coefficient, is an important property of a drug as it 
can influence several physiological properties like transport through membranes, 
rate of metabolism and interaction with receptor binding sites. High logP value is 
associated with increase in adverse effects in toxicity studies [106]]. This could be 
one of the probable reason behind adverse effects of BDQ. 
 
Being aware of the persisting issues of development of drug resistance and the 
attrition rate in the drug development pipeline, studies of novel drug targets are 
always necessary. ATP synthase enzyme is one recently discovered targets, which 
has been in the limelight of TB drug discovery in the past decade. Finding new 
targets in ATP synthase enzyme complex which would not have the drawbacks 
associated with the known BDQ target c-ring, could be a significant advancement 
in the current TB drug discovery studies. 
 
The newly proposed model of BDQ mechanism of action, [89] by our 
collaborators shows that BDQ also targets the ε subunit in addition to the membrane 
bound c-ring. Unlike the c ring, the ε subunit is located in the cytoplasmic portion of 
the bacterial cell (fig 1.3). Therefore, if new generation of diarylquinolines are 
developed which target specifically the ε subunit, it might be able to solve the current 
problems associated with BDQ. However, this above model is based on some 
structural biology and biochemistry studies which needs to be confirmed in intact 












us to major goal of this PhD project – To provide genetic evidence that the ε 
subunit is also a target of the BDQ drug. 
 
Like mentioned before, mycobacterial ATP synthase is an attractive drug 
target which if explored more, might yield interesting findings. The ε subunit of 
mycobacterial ATP synthase being a part of the central stalk plays a major role in 
coupling and regulation of ATP synthesis and hydrolysis. However, the exact role 
of the different domains of this subunit have not been identified yet. Structural 
biology studies by our collaborators predicts that the terminal residues of the CTD 
of the ε might play a significant role in the overall regulation function of the 
subunit. Again, this had to be confirmed, in the mycobacterial cells. That is the 
second important objective of the project. 
 
The overall approach of this project is to create different mutants as per the 
predictions from the structural studies conducted by our collaborators to answer 
the two objectives mentioned above. Recombineering method was employed for 
the creation of mutants in some of the essential genes in the atp operon. But 
recombineering being a new technique in our lab, the first step of this project was 
to optimize the technique. Also, most of the genes being essential, viability of 
such mutants was doubtful. So, the project started off with optimizing the 
technique while creating a mutant in one of the essential genes which is known to 











The specific aims of this project were to: 
 
 
1) Optimize the recombineering technique by creating a known viable 
mutant (I66M) in one of the ATP synthase genes. 
 
2) Generate the BDQ-binding-related epsilon mutants in the atpC gene 
 
(coding for ε subunit) and microbiologically characterize these mutants and detect 
changes in growth behavior, if any. By performing Minimum Inhibitory 
Concentration (MIC) with BDQ we could then confirm the role of those residues 
with the drug. If any significant phenotype is observed, we shall then perform 
complementation experiment. 
 
3) Perform independent overexpression experiment to provide 
additional line of evidence for any new binding site. 
 
4) Generate C-terminal truncated ε mutants of different lengths by 
inserting STOP codons at specific sites of the DNA sequence and perform 
biochemical assays – ATP synthesis and ATP hydrolysis using inverted membrane 
 
vesicles from these mutants, to find the role of the ε-CTD in these processes. 


























































































2.1 Mycobacterium smegmatis mc
2
 155 as the surrogate model organism 
 
In this project, Mycobacterium smegmatis was selected as the surrogate model 
for Mycobacterium tuberculosis because there are several advantages to work 
with it. M. smegmatis is a saprophytic and unlike M. tuberculosis, it is not 
pathogenic and can be safely handled under Biosafety level 2 (BSL2) conditions 
without Biosafety level 3 (BSL3) requirement. In addition to that, M. smegmatis 
grows much faster (generation time approximately 3 hours) compared to that of 
M. tuberculosis (generation time approximately 24 hours). It requires almost 3 to 
4 weeks for M. tuberculosis to produce colonies on agar plate, whereas only 2 to 3 
days for M. smegmatis, therefore reducing the duration of experiments. 
 
Therefore, although not suitable for virulence or pathogenicity study, it was 
appropriate for this particular project due to the conservation of housekeeping 
genes and their functions in between the two species. 
 
 
2.2 Bacterial strains and culture condition 
 





155 (ATCC 700084) and the other M. 
smegmatis mutant strains were grown in Middlebrook 7H9 broth which is 










glycerol, 0.0003% catalase and 0.05% Tween80 at 37°C with agitation. The broth 
cultures were usually grown in T25 flasks in a rocking shaker?? to facilitate aeration. 
For determination of the CFU, dilutions of cultures were plated on Middlebrook 
7H10 agar plates which were supplemented with 0.5% bovine albumin, 0.2% 
glucose, 0.085% NaCl, 0.5% glycerol, 0.0003% catalase and 0.006% oleic acid. The 
plates were usually incubated for 48 -72 hours to see visible colonies. As per 
requirement, antibiotics were added to the culture media (broth or agar) for selection 
at the following final concentrations: rifampicin (Rif) – 





2.2.2 E. coli culture conditions 
 
Escherichia coli DH5α was mainly used for genetic manipulation. This strain was 
cultured in LB broth or on LB agar at 37°C with agitation. When required, 
antibiotics were added to the culture media (broth or agar) for selection at the 
following final concentrations: Kan – 50μg/ml; Hyg – 150μg/ml. 
 
 
2.3 Growth pattern and microbiological assay 
 




 155 strains were grown in 10 ml 7H9 at 37°C till it reaches 














10 ml culture with a starting OD600 of 0.05. The OD600 was measured every 3 
 





2.3.2 Minimum Inhibitory Condition (MIC) of antibiotic/ Dose Response curve 
 
Working stock of all antibiotics were prepared in distilled water or in 90% 
DMSO and then were filtered under sterile condition. To study to growth 
inhibitory effect of the antibiotics, a 96-well, transparent, round-bottom plate was 
used. A log phase bacterial culture with initial OD600 of 0.05 was inoculated in 
each of the wells with 200μl 7H9 media having a range of antibiotic concentration 
over the different wells with the drug concentration increasing 2-folds from 





































The plates were incubated at 37 °C in an orbital shaker. After 18-24 hours, the 
OD of the different wells were read using a TECAN plate reader. Bedaquiline was 
purchased from Genegobio (Los Angeles, US). 
 
 
2.3.3 Determination of intracellular ATP 
 
According to the manufacturer’s instruction as described previously [47] the 
BacTiter-Glo Microbial Cell Viability Assay (Promega) was used for measuring 
the ATP levels. 
 
In 96-well white opaque Nunc plates, 25μl of bacterial culture was mixed with 
equal volume of the pre-mixed BacTiter-Glo reagent at room-temperature. Then the 
plate is incubated for 5 minutes in the dark. The TECAN plate reader (Tecan Infinite 
M200 Pro) was used to record the luminescence at 1s integration time per well and 
displayed as relative luminescence unit. Blank (Reading for 25μl of media mixed 
with 25μl of reagent) was subtracted from the values of all other wells. 
 
A standard curve was generated using 10-fold serial dilutions of ATP (0.1 to 
100nM) across the wells in the culture media. The ATP amounts of all cultures were 
standardized using the standard curve. Then the amount of ATP per bacterium was 



















2.4 Biochemistry assay 
 
2.4.1 Preparation of inverted membrane vessicles from M. smegmatis 
 
For ATP synthesis and hydrolysis assays, purified membrane fractions 
(inverted vesicles) of M. smegmatis are required. ATP synthase is a membrane 
enzyme and the synthesis of ATP occurs in the F1 domain which remains in the 
cytoplasm. So, we cannot measure the ATP directly. But if these membranes are 
turned inside out, then the F1 domain will face outside and the ATP can be 
quantified. Such inverted vesicles are created by passing the cells through a 
narrow valve under very high pressure in a French press cell or microfluidizer. 
 
The bacterial culture was grown at first in 200 mL till log phase as previously 
described and then expanded to 2 L. Culture of OD600 0.6-0.7. Approximately 5 g 
(wet weight) of wild-type and mutant M. smegmatis strains were pelleted down. 
The pellets were then separately resuspended in 20 mL membrane preparation 
buffer (50 mM MOPS, 2 mM MgCl2, pH 7.5) which contain EDTA-free protease 
inhibitor cocktail (one tablet per 20 mL buffer, Roche) and 1.2 mg/mL lysozyme. 
 
At room temperature, the mixture was stirred for 45 min, and then 300 μL of 1 M 
 
MgCl2 and 50 lL DNase I was added to it, with continued stirring for next 15 min, 
also at room temperature. All the following steps were carried out on ice. An ice-
cooled microfluidizer (model M-110L, Microfluidics, Westwood, MA, USA) was 
used to lyse the bacterial cells by three passages at 18 000 psi. The lysed cells 











the supernatant which consisted of the membrane fraction was ultracentrifuged at 
45000 g at 4 °C for an hour. After discarding the supernatant, and the precipitated 
membrane fraction was finally resuspended in membrane preparation buffer 
containing 15% glycerol. This was aliquoted in small eppendorfs, snap-frozen and 
stored at -80 °C. 
 
 
2.4.2 Determination of protein concentration 
 
The concentrations of the proteins in the vesicles were determined by the 
Bicinchonic Acid Assay as per the protocol (BCA; Pierce, Rockford, IL, USA), 
using BSA as standard. IMVs were then stored at - 80 °C. 
 
 
2.4.3 ATP hydrolysis activity measurements 
 
To measure the ATPase activity of the Inverted Membrane Vesicles (IMVs) 
wild-type and mutant M. smegmatis mutant strains, a continuous ATP hydrolysis 
assay was performed. This assay is based on a reaction (Fig. 2.2) in which the 
hydrolysis of ATP is coupled to the oxidation of NADH. With each cycle of ATP 
hydrolysis, Phosphoenolpyruvate converts into pyruvate in presence of Pyruvate 
kinase (PK). Pyruvate is subsequently converted to lactate by L-lactate 
dehydrogenase (LDH) resulting in the oxidation of one NADH molecule. 
 















the decrease of NADH absorption at 340 nm (Fig. 2.3) due to conversion into NAD, 
 























In this assay, ATP is constantly regenerated and oxidation of NADH to NAD 
is detected at a wavelength of 340 nm as described previously [107]. In brief, the 
samples were added at 37 °C to 1 ml of a reaction mix, containing 25 mM Hepes 
(pH 7.5), 25 mM KCl, 5 mM MgCl2, 5 mM KCN, 2 mM phosphoenolpyruvate, 2 
mM ATP, 0.4 mM NADH, 30 U L-lactic acid dehydrogenase and 30 U PK. The 
absorbance at 340 nm was observed with a spectrometer for 5 min. In case of 
IMVs the consumption of NADH by the type II NADH dehydrogenase (NDH-2) 
was inhibited by thioridazine. In addition, ATPase activity of IMVs was also 
measured in the absence of ATP and presence of thioridazine to identify any 
slight background oxidation of NADH, and to determine the amount of MgATP 













The absorbance change at 340  nm  is  measured  photometrically.  One  unit 
 




















2.4.4 ATP synthesis assay 
 
ATP synthesis can be measured by using the Luciferase assay for ATP 
synthesis, in which, luciferin in presence of ATP forms oxy-luciferin which emits 
luminescent signal. And this signal is directly proportional to the amount of ATP 



























This assay is performed in flat-bottomed white 96-well microtiter plates 
(Corning). The reaction mix comprised of assay buffer (50 mM MOPS, pH 7.5, 10 
mM MgCl2) containing lM ADP, 1M Pi and 1 mM NADH. The concentration of Pi 
was adjusted by addition of 100 mM KH2PO4 to the assay buffer. ATP synthesis was 
initiated by the addition of IMVs of the wild-type and mutant strains of M. smegmatis 
protein to a final concentration of 5 lg_mL_1. The reaction mixyure was incubated at 
room temperature for 30 min before adding 50 lL Cell- Titer-Glo reagent, followed 
by incubation for another10 min in the dark at room temperature. The luminescence 
produced, which correlates with the amount of ATP synthesized, was measured by an 
Infinite 200 Pro plate reader (Tecan), using the following parameters: luminescence; 




2.5 Genetic manipulations 
 
 
2.5.1 Plasmids and their source 
 
 
All the plasmids that have been used in this study are listed in Table 2.1. 
 
 
Table 2.1: List of plasmids used in this project and their sources. 
 
Plasmid Features Source 
   
 KanR, oriE and oriM,  
pJV62 Che9c gene 61 Hatfull [105] 
 (recombinase)  











 KanR, oriE and oriM,  
 Che9c gene 60  
pJV53 (exonuclease) Hatfull [105] 
 
 and gene 61  
 (recombinase)  
   
pSJ25 HygR, oriE, attP-int Hatfull [105] 
   
 KanR, Shuttle expression  
pMV262 vector with hsp60 Stover [109] 
 overexpression promoter  
   
pMVGBatpC pMV262+ atpC This study 
   
 
 
2.5.2 Mycobacterial genomic DNA isolation 
 
Due to the unique features of mycobacterial cell wall, a special protocol was 
used for its DNA extraction, adapted from Käser et al [110]. Mycobacterial cells 
were pelleted from a log phase culture of 50 ml. The pellet was resuspended in 
 
300μl of lysis buffer composed of 15% sucrose, 50mM Tris (pH 8.5), 50mM 
EDTA. 50μl of 100mg/ml lysozyme was added to the suspension with a final 
concentration of 10mg/ml and then incubated at 37°C for 1h. To this, 150μl of 
50mg/ml Proteinase K and 100μl of 10%SDS was added and again incubated at 
 
50°C for 1hr. The cell debris was then pelleted down by centrifugation at 14000rpm 
for 2 mins and the supernatant was collected in an Eppendorf tube. 500μl of Phenol-











supernatant and then the suspension was mixed by inverting the tube several 
times. Next, the aqueous phase was collected after another round of centrifugation 
at 14000 for 10 mins and transferred to a new Eppendorf tube. The phenol-
chloroform-isoamyl alcohol extraction was repeated twice. Then the aqueous 
phase was collected and 0.1 volume of 3M sodium acetate and 1 volume of 
isopropanol was added. This step results in precipitation of DNA. The tube 
containing DNA was kept in -80°C for 30min which further helps in DNA 
precipitation. Finally, the precipitated DNA was centrifuged, washed with 70% 
ethanol at 4°C, air dried and resuspended in 50μl nuclease-free water overnight at 
4°C. Next day the DNA was quantified and purity checked in a Nanodrop, diluted 
to desired concentration and stored at -20°C. 
 
 
2.5.3 Preparation of electrocompetent cells 
 
2.5.3.1 Preparation of electrocompetent cells of wildtype or mutant strains 
 
200ml of M. smegmatis (wild-type or mutant strains, whichever required) log 
phase bacterial cultures (OD~0.6-0.8) were harvested and incubated on ice for 1.5h. 
Then the cells were pelleted down by centrifugation for 10min at 4°C/3500rpm. The 
pelleted cells were washed 4 times with sterile 10% glycerol (maintained at 4°C) in 
decreasing volumes in every wash: 200ml, 100ml, 50ml, 25ml. After the final round 













electrocompetent cells were made into small aliquots of about 100-120μl in 
eppendorf tubes and kept in -80°C for future use. 
 
 
2.5.3.2 Preparation of electrocompetent recombineering cells 
 
M. smegmatis/pJV62 or M. smegmatis/pJV53 recombineering strain from pre-
culture was inoculated in 7H9 induction media (7H9 + 0.2% succinate + 0.025% 
Tween + Kan) and grown to mid-log phase (OD600 0.4-0.6). Acetamide (final 
concentration of 0.2%) was then added to the culture and further incubated for 3h 
to induce expression of the recombinase or exonuclease in the recombineering 
plasmid (pJV62/pJV53). Afterwards, these cells were made electrocompetent 
similarly as described in section 2.6.3.1. 
 
 
2.5.3.3 Preparation of electrocompetent E. coli cells 
 
200ml of E. coli cultures (OD600>1.0) were grown as mentioned before. The 
culture was kept on ice for 20min. It was then centrifuged for 10min at 
4°C/3000rpm, and the pelleted cells were washed with pre-chilled sterile 10% 
glycerol, 3 times, at decreasing volumes in succession: 200ml, 100ml, 50ml. The 
final cell suspension was concentrated in 2-4ml. The electrocompetent cells were 
















2.5.4 Transformation of electrocompetent cells 
 
2.5.4.1 Transformation of electrocompetent M. smegmatis cells. 
 
The eletrocompetent M. smegmatis cells were taken out from -80°C and thawed 
on ice for 2-3 mins. 100μl of thawed the electrocompetent cells was mixed with 
 
DNA substrates (double-stranded or single stranded oligonucleotides and/or 
plasmid) (50-500ng, less than 5μl) and transferred to pre-chilled 0.2cm gap 
electroporation cuvettes (Bio-rad, 1652086). These cuvettes were incubated on ice 
for 10 min, dried with tissue paper and then pulsed at 2.5kV, 25μF, 1000Ω (Bio-
rad Gene Pulser Xcell system). The time constants were around 20-25 ms. 
 
Immediately after electroporation, 1ml of warm 7H9 broth was added to the 
cuvettes and the cultures were transferred to 2ml eppendorf tubes and recovered at 
37°C 200rpm for 4h, after which appropriate amount of the cultures were plated 
in different dilution ranges on agar plates with selective antibiotic(s) and 
incubated for 2-3 days. 
 
To obtain recombineering strain, 50ng of plasmid pJV62 or pJV53 (as required 
for single stranded and double stranded recombineering respectively) was 
transformed into electrocompetent M. smegmatis as described above. Colonies 
growing on Kan plates (having been successfully transformed with the plasmid) were 
inoculated in 10ml 7H9 media containing 25μl/ml Kan. Stock of these M. 













of sterile 50% glycerol into the log phase OD600 ~1.0 cultures, and then aliquots 
were made in cryovials and kept at -80 °C for future use. 
 
 
2.5.4.2 Transformation of electrocompetent E. coli cells 
 
Electrocompetent E. coli cells were used to construct plasmids for 
complementation and overexpression experiments. Aliquots of the eletrocompetent 
E. coli cells were thawed on ice. To the 100μl of thawed electrocompetent cells 
 
2.5μl from 10μl ligation mixture was added in pre-chilled 0.2cm gap cuvettes. The 
cuvettes were incubated for 2min on ice, dried with tissue paper and pulsed at 3kV, 
 
25μF, 200Ω. The time constants were usually between 4.8-5.2 ms. After 
electroporation, 1ml of warm LB was immediately added to the cuvettes and the 
cultures were transferred to round-bottom tubes and recovered at 37°C 200rpm for 
 
1h, after which appropriate amount of the cultures (usually 100μl and 900μl) in 










 and M. smegmatis
R37G 
 
These mutants were generated by using point mutation recombineering strategy 
adapted from van Kessel and Hatfull [105]. Briefly, site-directed, genome 










as described previously [102] [98]). The M. smegmatis
I66M
 mutant was 
generated using single-stranded recombineering (recombineering plasmid used 
pJV62). Remaining all other mutants were generated using double-stranded 
recombineering (recombineering plasmid used pJV53). 
 
Electrocompetent M. smegmatis harboring recombineering plasmid and thus 
expressing the mycobacterial phage Che9c recombineering genes gp60 and/or 
gp61 was transformed with the double-stranded or single-stranded 80-90 
nucleotide DNA oligonucleotide (as the case required) DNA oligonucleotide 
(synthesized by Integrated DNA Technologies, USA). 
 
The oligonucleotide was designed in such a way that it contained the desired 
codon to replace the specific genomic codon at the centre. Colonies were PCR 
screened with 2 different primer pairs. For colonies that were found positive in 
PCR screening, the introduction of the desired mutation was verified by 
sequencing (AIT Biotech, Singapore). 
 
 
2.5.5.1 Design of ssDNA/dsDNA oligo for point mutation 
 
A ssDNA oligo (for M. smegmatis
I66M
) or dsDNA oligo (M. smegmatis
W16A




) was designed based on van Kessel’s paper (131). For ss-
recombineering, the mutation to be introduced was placed at the center of the ssDNA 
90nt-long. For ds-recombineering, at first 100bp oligo (dsDNA_a) with the mutation 











(Ext_b and Ext_c) primers, this 100bp was extended to get a 200 bp AES. All PCR 
products in this part were amplified using phusion DNA polymerase (Thermo Fisher 
Scientific). A 50 μl PCR reaction mix was prepared: 37 μl dH2O was mixed with 10 
μl 5x Phusion GC buffer, 1 μl deoxyribonucleotide triphosphate (dNTP) 
(10 mM), 0.25 μl each primer (forward and reverse each 100 μM), 0.5μl Phusion 
 
High-Fidelity DNA Polymerase and 1 μl 100 bp ds template DNA (100 mM). 
PCR conditions were as followed: initial DNA denaturation was for 30 seconds at 
98°C, followed by 25 cycles of DNA denaturation (10 sec at 98°C), primer 
annealing (30 sec at 55°C) and extension (15 sec at 72°C). Final extension was 
done for 5 min at 72°C before the sample was cooled down to 4°C. 
 
To achieve a higher recombineering efficiency, for the ssDNA recombineering, 
substrate was designed to be complementary to the lagging strand. The strand on 
which the target gene locates is referred to as ‘+’ or ‘–’ in TB database 
 
(http://www.tbdb.org). For the genes, which fall within locus 0001-3334, if the 
gene is placed on the “+” strand, the ssDNA oligo should be reverse 
complementary to the coding sequence; if the gene is placed on the ‘–’ strand, the 
ssDNA oligo should be the same as the coding sequence. For genes fall within 
locus 3335-6947, the rule is opposite.100nmol of the ssDNA oligo was 
















The lyophilized ssDNA pellet received from IDT, was resuspended in nuclease-
free H2O to 250μM. All ssDNA or dsDNA oligonucleotide used for generating 
the different mutants are listed in Table 2.2. 
 
 








(ssDNA/dsDNA AES)  
  
















































2.5.5.2 Design of primers used for screening 
 
For all the mutations two pairs of screening primers were designed. Both the 
pairs contained the same forward (Frwd) primer. One pair contained the reverse 
primer- matching the wild-type codon, and one pair contained the reverse primer-
matching the mutated codon. All PCR products in this part were amplified using 
Taq DNA polymerase (Thermo Fisher Scientific). All primers pairs used for 
screening the different mutants are listed in table 2.3 of this chapter. 
 
As shown in table 2.3, in each case, the reverse primer (Rev_a) has the same 
sequence as wild-type allele, thus binds to wild-type gDNA, while reverse primer 
(Rev_b) aligns with the mutant allele thereby binds to mutant gDNA. Due to the 
mismatch in the 3’ end, primer (Rev_a) should not be able to bind to mutant gDNA 
but will give a band for wild-type gDNA, and vice-versa for primer (Rev_b). 
 
However, that was not always the case, i.e. some primers still result in 
amplified products inspite of having a 3’ mismatch i.e colonies showing positive 
using the mutant primer, when sequence verified, still showed wildtype or mixed 
results. This could be possibly due to presence of mixed colonies of mutant and 
wild-type. Therefore, the strategy used for screening was as follows. 
 
 
2.5.5.3 Screening for mutants 
 
50 recovered colonies from the 7H10-Kan-Hyg plate were picked and 











performed with screening primers. First, using the primer (Rev_b) along with the 
corresponding forward primer, the colonies were screened. Colony showing 
brightest band in this PCR, was considered to have the desired mutation. This 
particular colony was then streaked out again to get single colonies. All screening 
primers for the mutations are listed in Table 2.3. 
 
For all colony-PCR reactions, for screening of the mutants, Taq DNA 
Polymerase (recombinant) kit purchased from Thermo Scientific was used. For 
 
1xreaction mixture (30 μl) 20.5 μl dH2O was mixed with 3 μl 10x Taq buffer with 
(NH4)2SO4(-MgCl2), 2.4 μl MgCl2 (25mM), 0.6 μl dNTP (10mM), 0.15 μl each 
primer (forward and reverse), 0.2 μl Taq DNA Polymerase and 3 μl of the heated 
cell culture. The conditions of PCR were as followed: initial DNA denaturation 
was for 3 min at 95°C, followed by 25 cycles of DNA denaturation (30 sec at 
95°C), primer annealing (30 sec at 55°C) and extension (30 sec at 72°C). Final 
extension was done for 5 min at 72°C before the sample was cooled down to 4°C. 
 
A 1% w/v agarose gel was prepared and samples were run at a constant 
voltage of 70V. 
 
At least 50 new single colonies were tested again, but this time using primer 
(Rev_a). So, the colonies showing ‘positive band’ in this PCR implied that they 
are still mixed with wild-type gDNA; while the colonies showing ‘no band’ meant 














If such ‘no band’ colonies aren’t found in this round, the streak-out and PCR 
testing of 50 new colonies is repeated until we find one. This purely mutant colony 
was further once again tested with the primer (Rev_b) to make sure it gives 
 
‘positive band’ with the primer matching the mutant codon. Positive colonies were 
amplified using flanking primers and sent for sequence verification AIT Biotech. 
 
 
Table 2.3: List of primers used for screening mutants related to BDQ binding. 
 
Screening Primer Sequence (5’

 3’) Tm(°C) 
   
I66M Frwd GCGCCATGAAGGCCAGGGTC 66.6 
   
I66M Rev_a CGCCATGAAGGCCAGGTTGAT 63.2 
   
I66M Rev_b CGCCATGAAGGCCAGGTTCAT 63.2 
   
W16A Frwd CTGGACCCGGCGATCGTCGG 66.6 
   
W16A Rev_a CGAACGTAGCGGGTCCGGACC 67.4 
   
W16A Rev_b CGAACGTAGCGGGTCCGGACGC 67.8 
   
R37G Frwd GCGACGACGTTCGCCCACCTGG 68 
   
R37G Rev_a CCACGAGCGGGATGTGCCG 66.1 
   
R37G Rev_b CCACGAGCGGGATGTGCCC 66.1 

















2.5.5.4 DNA sequencing and analysis 
 
DNA samples were sent for sequencing to AITbiotech in Singapore and were 
prepared as per their instructions. They performed capillary electrophoresis 
sequencing with the same primers used for flanking PCR. DNA sequences were 
aligned to wild type M. smegmatis mc
2
 155 gene atpC (coding for epsilon subunit) 
taken from National Center for Biotechnology Information (NCBI) gene databank. 
 
 
2.5.5.5 Removing the recombineering plasmid pJV62 
 
The confirmed mutant colony was inoculated to 10ml 7H9 with Hyg and then 
subcultured in 7H9-Hyg for 2-3 days. This culture was streaked out on antibiotic-
free 7H10 plates. Replica plating was done for colonies from this plate onto 
7H10-Hgy and 7H10-Kan grid plates. 
 
Only the colonies which were no more resistant to Kan and still sensitive to 
Hyg were considered to be free of pJV62. If no such colonies were found in one 
round, the cycle of re-streaking and replica plating is repeated. Once the plasmid 



























For generating mutants with truncated c-terminal (M. smeg
1-101
 and M. smeg
1-
120
) of the epsilon subunit of mycobacterial F-ATP synthase, the stop codon TAG 
was introduced at the specific positions 102 and 121 respectively. As previously 
described for the BDQ-binding mutants, here also, double stranded 100 bp DNA 
oligonucleotides (1_101 dsDNA_a, 1_120 dsDNA_a) carrying these aforesaid 
mutations at specific positions of the gene atpC was synthesized by Integrated 
DNA Technologies, USA (Table 2.4). This oligonucleotide was further expanded 
by 80 bp by an extension PCR with the forward and reverse extension primers 
(Table 2.4) to generate a 200 bp dsDNA oligonucleotide AES (allelic exchange 
substrate). All oligonucleotides and primers pairs used for generating and 
screening the different truncation mutants are listed in Table 2.4 and 2.5 of this 
chapter. The remaining steps of recombineering were same as that already 
described for the BDQ binding mutants. 
 
























1_101 Ext_b TTCCTGTCGGTGACCGAGGAGACCGTCCGGATCCTCGTGGAGAACGCACAAT 
 TCGAGTCCGAGATCGACGCGGATGCTGC 
  
1_101 Ext_c CGCGACCATGCCGATCATGGACGCGCTCATCGATGTGACTAGTCGATCTGGC 
 CGAGGGCGCGCAGCCGCGCCCGGCCCCA 
  
1_120 dsDNA_a GCGGACCGCGGCATGGGGCCGGGCGCGGCTGCGCGCCCTCGGCCAGATCTA 
 GTAGTCACATCGATGAGCGCGTCCATGATCGGCATGGTCGCGCTCATCG 
  
1_120 Ext_b TCCGAGATCGACGCGGATGCTGCCAAGGAAGACGCAGCATCCGACGACGAG 
 CGGACCGCGGCATGGGGCCGGGCGCGGCT 
  





Table 2.5: List of primers used for screening truncation mutants. 
 
Screening Primer Sequence (5’

 3’) Tm(°C) 
   
1_101 Frwd CGCTTCCTGAGCCAGAACA 59.5 
   
1_101 Rev_a CGGTCCGCTCGTCGTC 58.4 
   
1_101 Rev_b CGGTCCGCTCGTCCTA 57 
   
1_120 Frwd CGCTTCCTGAGCCAGAACA 59.5 
   
1_120 Rev_a CGCTCATCGATGTGACTAGTC 61.2 
   
1_120 Rev_b CGCTCATCGATGTGACTACTA 60 





















2.5.7 Generation complemented strain: ‘W16A comp atpC’ 
 
This part of the experiment (construction of pMVGBatpC) was done in 
collaboration with Dr. Goran Biukovic from our lab. For complementation 
studies, a PCR-amplified gene atpC from the wild-type M. smegmatis mc
2
155 
strain is ligated into BamHI/PstI restriction sites of vector pMV262 [109] and 
constitutively expressed under the promoter hsp60 (Figure 2.4). 
 
Pst I (2) 
atpC Eco RI (3)  





















Fig. 2.5: The construct pMVGBatpC (pMV262+ atpC); OriM is the origin of replication in 




Amplification of the gene and deletion of internal BamHI restriction site are done 
by PCR (initial denaturation: 98
o





seconds), final amplification 72
o













atpC, and Rev-atpC, Inter Frw-atpC and Inter_Rev-atpC (Table 2.6). The sequence 
 
was confirmed from AIT Biotech. 
 
 




 3’) Tm(°C) 
   
Frw-atpC GGTGTGGATCCGCTGATCTGAACG 68.5 
  
   
Rev-atpC ATGGACGCTGCAGTCGATGTGACTAG 69.5 
   
Inter_Frw-atpC GAGACCGTCCGAATCCTCGTGGAG 70.6 
   
Inter_Rev-atpC CTCCACGAGGATTCGGACGGTCTC 70.4 




Electrocompetent cells of the M. smegmatis
W16A
 mutant strain was prepared 
as previously described in section 2.6.3.1. These electrocompetent cells were later 
transformed with the construct pMV GBatpC by electroporation as previously 
described in section 2.6.4.1 and selected on Kan agar plates. Colonies were picked 





2.5.8 Generation of overexpression strain: ‘wt overexpr atpC’ 
 
To generate the ‘wt overexpr atpC’ overexpression strain, the same 
construct pMV GBatpC was used. This plasmid was introduced in the wild type 







































Creation and characterization of 
a known viable BDQ-resistant 














“Without a solid foundation,  












As discussed before in chapter 1, recombineering has quite a few advantages 
compared to classical genetic engineering. In this project, we came upon the idea 
to use recombineering technique to create our desired mutants in the M. 
smegmatis genes. All the mutants, relevant to this project, were to be made in the 
essential gene atpc which codes for the epsilon subunit in the ATP synthase 
enzyme complex. First few failed attempts in creating one of the desired epsilon 
mutants, made us ponder, is it because of any technical faults or is it because such 
mutations in an essential gene are simply not viable. 
 
In any case, it was realized that the first step of this project would be to 
optimize the recombineering protocol, a method which was relatively new in our 
lab. And to do so, we decided to make previously known viable mutation, I66M, 
in the relevant gene atpE, coding for subunit c of the enzyme complex. This 
mutant have been isolated before in spontaneous resistance mutation experiments 
with BDQ [79]. In that study, all the 8 atpE resistant mutants in the M. smegmatis 
species had this specific point mutation I66M, which implied the importance of 
this residue in BDQ interaction. Also, once made, this I66M mutant would serve 
as a resistance benchmark to compare other mutants related to BDQ mechanism 
of action, that we would create in subsequent stages of the project. Different 
recombineering conditions were used while creating the mutant, in order to find 













With or without a co-transformation plasmid 
pSJ25 or pmRFP as co-transformation plasmid 
 
Lagging or Leading strand as the oligo-nucleotide for ss-
recombineering 
 
In this chapter, we discuss the findings from our optimization experiments 
 













 cfu/ml when grown in the presence or absence of kanamycin (Table 3.1). 
There was no significant difference observed between cells grown with or without 
kanamycin implying that the plasmid pJV62 (which has kanamycin resistance 
cassette) has been retained in most cells during preparation of electrocompetent 
cells (Table 3.1). Therefore, the gene Che9c-gp61 coding for recombinase has 
been likely expressed. 
 
The same batch of cells were used for preparing all the mutants in the atpE 






















Table 3.1: Cell density of the electrocompetent cells prepared. Cell density, defined by colony 
forming units/ml cell suspension (cfu/ml), of M. smegmatis mc2 155 containing plasmid pJV62 
 
Strain Cell density cfu/ml 
   
M. smegmatis mc
2
155 In presence of Kanamycin In absence of kanamycin 
containing   
   





   
 
 




155 containing either pmRFP or pSJ25 
 
Transformation efficiency is an important parameter in recombineering process 
which determines the ability of the cell to take up extracellular DNA. It is calculated 
as the number of obtained colony forming units per μg of injected DNA (cfu/μg 
 
DNA). It depends on a number of factors like – strain of the bacteria, growth 
phase of the bacteria, media, DNA properties etc. Two different plasmids, namely 
pmRFP (an integrative plasmid) and pSJ25 (an episomal plasmid), were isolated 
from the stock of E. coli DH5α strains containing those plasmids. The 
transformation efficiency was found to be almost twice as high when M. 
smegmatis containing pJV62 were transformed with pSJ25 (1x10
6
 cfu/μg DNA) 
than with pmRFP (5x10
5
 cfu/μg DNA) (Table 3.2). So, it was decided that, if a 















Table 3.2: Transformation efficiency for M. smegmatis mc
2
 155 prepared containing 
pJV62 transformed with either plasmid pmRFP or pSJ25. It is calculated by dividing the 




 155 M. smegmatis mc
2
 155 













3.3 Construction of the mutant M. smegmatis atpE
I66M 
 
3.3.1 Comparison of the recombineering frequency under several conditions. 
 
Single stranded DNA oligonucleotides were designed to introduce the specific 
point mutation I66M in the atpE gene coding for the c subunit of ATP synthase 
enzyme as described earlier in chapter 2. The designed leading single-stranded 
oligonucleotide used for recombineering is the coding strand and contains the 
targeted point mutation in the middle, whereas the lagging strand is the reverse 
complement of the leading strand. The objective was to compare and confirm 
which strand has more recombineering frequency. 
 
After having chosen the co-transformation plasmid pSJ25, it was important to 
confirm whether using this plasmid would have any advantages at all, because using 
it would involve an additional step of its removal at the end. The logic behind using 












this plasmid are introduced at the same time and condition, some of the cells 
which take up the plasmid (and therefore can be selected by antibiotic resistance), 
must also take up the oligonucleotide. 
 
Using recombineering technique, the oligonucleotides (leading and lagging 
strand) were introduced in the electrocompetent cells with and without co-
transformation plasmid pSJ25. After transformation, 100 colonies were selected 
and streaked in a master-grid-plate. Colony PCR was performed, and mutants 
were screened using specially designed primers which would anneal to the mutant 
DNA and not the wild type DNA. Based on the number of such positive bands in 
the agarose gel (Fig 3.1), the recombineering frequency under each condition was 












Fig. 3.1: 1% DNA agarose gel of colony PCR to screen for M. smegmatis atpE recombinants 
containing point mutation I66M. In this gel picture, three colonies (no. 4,5,10) shows bright band 
implying it has mutant DNA while the remaining don’t. Amplicon size ~600 bp 
 
 
Table 3.3 shows a comparison of the recombineering frequency under each of 
those conditions tested. It is evident that the maximum number of mutants were 











Table 3.3: Comparison of the recombineering frequency under different conditions 
 
No. Conditions Recombineering freuency 
   
1 Recombineering strain + leading strand -- 
   
2 Recombineering strain + lagging strand 2/100 (2%) 
   
3 Recombineering strain + leading strand 2/100 (2%) 
 + pSJ25  
   
4 Recombineering strain + lagging strand 11/100 (11%) 
 + pSJ25  
   
 
 
Therefore, it was decided for our subsequent recombineering experiments, using 
a co-transformation plasmid would increase the chances of having a mutant in the 
colonies screened. Also, if we use single stranded recombineering, it was evident that 































































Fig. 3.2: DNA sequence chromatograms showing the point mutation (ATG) introduced into the 
isoleucine codon number 66 (ATC) of the c subunit encoding atpE, thus generating M. smegmatis 
atpC
I66M
 in which isoleucine is replaced by methionine. 
 
As shown in Fig. 3.2 the mutation I66M was confirmed by sequencing. 
 
 




Having successfully introduced the I66M point mutation in the atpE gene, we 
 
















curve experiment and testing the BDQ susceptibility of the new mutant by doing a 
drug susceptibility test. 
 
 
3.4.1 Growth curve 
 
To confirm that this mutation has not affected the growth or fitness of the 
bacteria, a broth culture growth curve comparison of the M. smegmatis atpE
I66M
 
























Fig. 3.3: Growth of wild type M. smegmatis and the mutant in liquid medium. ‘wt’: wildtype M. 
smegmatis; ‘I66M’: M. smegmatis atpCI66M. The experiments were carried out three times 
independently. Mean values with standard deviations are shown. 
 
 
As expected, there was no change in the growth behavior of the mutant that was 
 
















3.4.2 BDQ susceptibility comparison 
 
To confirm that the amino acid residue change I66M is involved in the BDQ 
binding as described previously in literature [79], a drug susceptibility – dose 



























Fig. 3.4: BDQ susceptibility – Dose response curves of wildtype M. smegmatis and its genetic 




It was predicted that this amino acid exchange would affect the BDQ 
susceptibility of the bacteria. As shown in figure 4.5 it was observed that whereas 
wild type M. smegmatis showed a MIC
50
 of 10 nM, the mutant M. smegmatis 
atpC
I66M
 showed an MIC
50
 of 120 nM, which means, the mutation resulted in an 












from literature, that the isoleucine residue in the 66
th
 position plays an important 





The  findings  from  this  chapter,  were  very  important  to  standardize  the 
 
recombineering technique for the subsequent experiments in the next chapters. To 
 
summarize the findings: 
 
Using a co-transformation plasmid along with the oligonucleotide, 
would increase the recombineering frequency, and so should be used. 
 
An episomal plasmid pSJ25 would be preferable to an integrative 
plasmid pmRFP, to be used as the co-transformation plasmid. 
 
If using ss-recombineering, a lagging strand oligonucleotide would 
have more chances to generate a mutant compared to the leading 
strand oligonucleotide. However, for certain mutations in gene atpC, it 
was interesting to observe that double-stranded recombineering had 
more recombineering frequency compared to single-stranded 
recombineering. Therefore, ds recombineering technique was adopted 
to produce certain mutants in this project. 
 
It is important to note that while creating the mutant I66M, we 
encountered a problem of mixed DNA of wildtype and the mutant in 












repeated PCR-screening and streaking out to get single colonies, we 
could not identify the exact reason behind this persisting problem. As 
it will be observed in the next few chapters, this same approach was 
taken for the epsilon subunit mutants as well. 
 
For the first time a mutation was introduced artificially to create a 
previously known BDQ spontaneous resistant mutant. 
 
The isoleucine residue having a strong binding affinity for the drug, the 
mutant would serve as a resistant benchmark. The I66M could even serve 
as a background mutation for subsequent mutations in epsilon subunit 






































































Bedaquiline targets the Epsilon subunit of 













Findings from this chapter have been published in the following manuscript: 
 
Kundu, Subhashri, Goran Biukovic, Gerhard Grüber, and Thomas Dick. 
 
"Bedaquiline Targets the ε Subunit of Mycobacterial F-ATP Synthase." 















The main objective of this PhD project is to investigate a second binding site of 
the BDQ drug in the epsilon subunit of mycobacterial ATP synthase complex. To 
understand the role of specific amino acid residues in this drug binding, our approach 
is to perform point mutations of those residues via recombineering and look for 
phenotypic changes in the mutants. Here it is important to mention that we focused 
on the W16 and R37 amino acids residues specifically. The other amino acids 
mentioned in the structural study [89] like - F50 was not chosen as it is in subunit c 
while the T19 was not chosen as it is not conserved in M. smegmatis. The findings of 
these experiments will be discussed in the current chapter. 
 
 




The amino acid sequence of atpC gene were aligned from different 
 
mycobacterial species as shown below in Table 4.1. 
 
Table 4.1: Amino acid sequence alignment of atpC gene coding for epsilon subunit across 13 
different mycobacterial species showing the W
16
 (yellow) residue is uniformly conserved across 
all species. The R
37
 (green) residue is mostly conserved with few exceptions. 
Organism DNA sequence of atpC gene 
 
 















  EGVSILAESAEFESEIDEAAAKQDSESDDPRIAARGR 
  ARLRAVGAID 
     
2 M. smegmatis MADLNVEIVAVEREL W SGPATFVFTRTTAGEIGILPR   
  HIPLVAQLVDDAMVRVEREGEDDLRIAVDGGFLSVTE 
  ETVRILVENAQFESEIDADAAKEDAASDDERTAAWGR 
  ARLRALGQID 
   
3 M. bovis MAELNVEIVAVDRNI W SGTAKFLFTRTTVGEIGILPR   
  HIPLVAQLVDDAMVRVEREGEKDLRIAVDGGFLSVTE 
  EGVSILAESAEFESEIDEAAAKQDSESDDPRIAARGR 
  ARLRAVGAID 
   
4 M. africanum MAELNVEIVAVDRNI W SGTAKFLFTRTTVGEIGILPR   
  HIPLVAQLVDDAMVRVEREGEKDLRIAVDGGFLSVTE 
  EGVSILAESAEFESEIDEAAAKQDSESDDPRIAARGR 
  ARLRAVGAID 
   
5 M. leprae MDELNIEIVAVDRKI W SGKGTFLFTRTTAGEIGILPR   
  HIPMVAQLVDDNMVRIEREGEKDLRVAVDGGFLSVTE 
  ERVSILAESAEFDSEIDENAAKQDAESDDPRIAARGR 
  ARLRAVGAID 
   
6 M. avium MAELNVEIVAVDRKI W SGEATFLFTRTTVGEIGILPR   
  HIPLVAQLVDDAMVRVEREGEDDLRIAVDGGFLSVTE 
  ETVTILAESAEFSSEIDESAAREAAESDDPRVAARGR 
  ARLRAVGAID 
   
7 M. fortuitum MADLNVEIVAVEREL W SGTATFVFTRTTAGEIGILPR   
  HIPLVAQLVDDAMVRVEREGEDDLRIAVDGGFLSVTE 
  ETVRILVENAQFESEIDADSAKRDAESDDEQTAAWGR 
  ARLRALGQID 
   
8 M. canettii MAELNVEIVAVDRNI W SGTAKFLFTRTTVGEIGILPR   
  HIPLVAQLVDDAMVRVEREGEKDLRIAVDGGFLSVTE 
  EGVSILAESAEFESEIDEVAAKQDSESDDPRIAARGR 
  ARLRAVGAID 
   
9 M. MAELNIEIVAVDRKI W SGKGTFLFTRTTVGEIGILPR   
 haemophilum HIPVVAQLVDDAMVRVEREGEKDLRVAVDGGFLSVTE 
  EGISILAESAEFESEIDEHAAKQDAESDDPRIAARGR 
  ARLRAVGAID 













10 M. xenopi MAEMDVDIVDVDRKM W SGKATFIFTRTTVGEIGIMPR   
  HIPLVAQLVEDAMVRVEREGEEDLRIATHGGFLSVTE  
  DGVTILAESAEFASEIDEATARHDAQSGDPRIAAQGR  
  ARLRALGVLD  
    
11 M. kansasii MAELNVEFVAVDRKI W SGKATFLFTRTTVGEIGILPN   
  HIPLVAQLVDDAMVRLEREDDKDLRVAVDGGFMSVTE  
  DGVTILAESAAFESEIDESAAKHDAESEDPRISAKGR  
  ARLRAIGAID  
    
12 M. gordonae MSELNVQIVAVDREI W SGEATFLFTRTTAGEIGILPH   
  HIPLVAQLVDDAMVRVEREGEDDLRIAVDGGFLTVTE  
  EGVSVLAESAEFEKDIDESAARQDSESDDPQVAARGR  
  ARLRAVGALD  
    
13 M. abscessus MSEIDVEIVAVEREI W SGKATFVFTRTTSGEIGILPH   
  HIPLVAQLVDDAAVKIEREGSDDLWWAIDGGFLSITD  
  TKVSILAESAQARADIDEAKAKTDSGSEDPRVAAQGR  
  ARLRALGQT  
       
 
 
As seen from the above table, the W16 amino acid, which is uniformly 
conserved across mycobacterial species, was predicted from the structural biology 
studies [89], to be an important amino acid in the BDQ interaction with the 
epsilon subunit. The amino acid R37, also predicted by the structural studies to 
support the BDQ bindings conserved in most of the mycobacteria except in M. 
kansasii, M. gordonae and M. abscessus. 
 
While the BDQ binding model was predicted in M. tuberculosis, we carried 
out mutagenesis experiment in surrogate model M. smegmatis. So, it is very 
important that this amino acid be conserved in both the species for the model to 























According to the binding model, the most important residue in the ε subunit 
 
involved in the BDQ binding was W16. So, to understand it’s specific role this 
crucial tryptophan amino acid residue in the 16
th
 position was decided to be 
replaced with Alanine using recombineering [111][102]. Interesting to note, 
tryptophan that carries a larger side chain is being replaced with alanine that is 
with a smaller side chain. The significance of this replacement will be discussed 
later in this chapter. 
 
 




The mutation W16A was made using the recombineering technique as 
described previously. Colony PCR using specially designed primers that could 
amplify specifically the mutant but not the wildtype DNA. Colonies showing 
brightest band was considered to have mutant DNA. The figure below shows, 











































Fig. 4.1: 1% DNA agarose gel of colony PCR to screen for M. smegmatis atpC recombinants 
containing point mutation W16A. In this gel picture, only one colony (no. 11) shows bright band 
implying it has mutant DNA while the remaining don’t. Amplicon size ~480bp. L is the 1kb ladder. 
 
But as mentioned before in chapter 2, even such positive bands colonies could 
not discriminate the probability of having wt DNA mixed with the mutant DNA 
as it was seen from some of the initial sequencing results. So, multiple rounds of 
screening and passage-streaking had to be done to get single colonies with pure 
mutant DNA, free of any wildtype DNA. In this particular case, for getting pure 
W16A mutant, 17 such rounds of screening were performed! 
 
The positive colony from the above PCR (Fig. 4.1) was again streaked to get 
single colonies. From here, 50 more colonies would then be screened using 
another set of primer which amplifies only with wildtype. Absence of any band in 
such a gel indicated that it is a pure mutant colony. DNA from such a colony was 

















































Fig. 4.2: DNA sequence chromatograms showing the two point mutations (GCG) introduced into 
the tryptophan codon number 16 (TGG) of the ε subunit encoding atpC, thus generating M. 
smegmatis atpC
W16A
 in which tryptophan is replaced by alanine. 
 
After sequencing confirmation of the mutant strain (Fig. 4.2), the recombineering 
plasmid was removed by several round of passaging and further phenotypical 
















4.3 Phenotypic characterization of the mutant M. smegmatis atpC
W16A 
 
4.3.1 Growth comparison on solid agar medium 
 
The colonies morphology in solid agar media was observed and compared with 
 


















Fig. 4.3: Growth of wild type M. smegmatis and its genetic derivative on solid medium. Colonies 
are shown after 4 days of incubation. ‘wt’: wildtype M. smegmatis, ‘W16A’: M. smegmatis 
atpCW16A, ‘W16A comp atpC’: M. smegmatis atpCW16A complemented with a wild type copy 
of the gene encoding the ε subunit via the introduction of plasmid pMV262-atpC. 
 
As evident from Fig. 4.3, the mutation did not affect the colony morphology, as 
the mutant W16A looks indistinguishable from the wild type M. smegmatis. 
 
 
4.3.2 Growth comparison in liquid medium 
 
. The mutant strain was then subjected to growth curve experiments in broth 














































Fig. 4.4: Growth of wild type M. smegmatis and its genetic derivative in liquid medium. ‘wt’: wild 
type M. smegmatis; ‘W16A’: M. smegmatis atpCW16A, ‘W16A comp atpC’: M. smegmatis 
atpC
W16A
 complemented with a wild type copy of the gene encoding the ε subunit via the 
introduction of plasmid pMV262-atpC. The experiments were carried out three times 




In the growth curve experiment, as seen from Fig. 4.4, there was no significant 
difference in the generation time (3.5 hours) or growth pattern (the different strains 
reached the stationary phase around 22 hours) between the strains. This implied that 














4.3.3 BDQ susceptibility comparison 
 
Whether the amino acid residue W16 in the ε subunit of mycobacterial ATP 
synthase is involved in the binding of BDQ drug is the main objective of this 
project. To answer this question, BDQ susceptibility of the bacterium i.e. growth 































Fig. 4.5: BDQ susceptibility – Dose response curves of wild type M. smegmatis and its genetic 




‘W16A comp atpC’: M. smegmatis atpCW16A complemented with a wild type copy of the gene 
encoding the ε subunit via the introduction of plasmid pMV262-atpC. The experiments were 
















It was predicted that this amino acid exchange would change BDQ 
susceptibility of the bacteria, either to hypo sensitivity, if the drug binds more 
weakly to the mutated form of the ε subunit, or to hyper sensitivity, if the 
mutation allows stronger binding. 
 
As shown in Fig. 4.5, it was observed that whereas wild type M. smegmatis 
showed a MIC
50
 of 10 nM, the mutant M. smegmatis atpC
W16A
 showed an 
MIC
50
 of 2 nM, which means, the mutation resulted in a 5-fold increased 
sensitivity to BDQ. 
 
The observed hyper-sensitivity of the bacterium may suggest that the 
replacement of the bulky tryptophan with an alanine provides more space for a 










To confirm that the hypersensitivity to BDQ observed in the M. smegmatis 
atpC
W16A
 strain was due to the specific amino acid exchange W16A, and not 
some other mutation elsewhere in the genome, complementation experiments 
were performed. The complementation experiment was done in collaboration with 












pMVGBatpC. A PCR amplified copy of the atpC from wild type M. smegmatis 
was ligated into BamHI/PstI restriction sites of vector pMV262 and constitutively 
expressed under promoter hsp60 (Fig. 4.6). 
 
Pst I (2) 
atpC Eco RI (3)  


























Fig. 4.6: Plasmid map of pMVGB atpC showing wild type atpC (green), hsp60 promoter (brown) 
 
and restriction sites BamHI/PstI. 
 
 
As described in Chapter 2, the wild type copy of atpC carried by the plasmid 
 
pMV262-atpC was introduced in the mutant strain M. smegmatis atpC
W16A















electroporation resulting in the creation of the complemented strain referred as 
W16A comp atpC. 
 
It is evident from Fig. 4.3 and Fig. 4.4, this strain had similar colony morphology 
and growth pattern in liquid media, as that of wild type M. smegmatis. 
 
When BDQ susceptibility test was performed, it was seen that this complemented 
strain had reverted to the wildtype phenotype of MIC50 = 10nM. Thus, it was 
confirmed that the 5-fold increase in BDQ sensitivity was due to the specific 
amino acid residue exchange W16A. 
 
 
4.4  Over-expression  experiment:  An  additional  independent  evidence 
 





To further confirm the finding from the previous set of experiments, that the 
specific W16 amino acid was involved in BDQ binding, an over-expression 
experiment was performed. As described in Chapter 2, the overexpression strain – 
 
‘wt overexpr atpC’ was created in which wild type M. smegmatis, is overexpressing 
wild type ε protein via introduction of pMV262-atpC (using the same construct 
pMVGB atpC). As described in Chapter 2, this was done by electroporation of the 













































Fig. 4.7: Growth of wild type M. smegmatis and its genetic derivative ‘wt overexpr atpC’: wild type 
 
M. smegmatis overexpressing wild type ε protein via introduction of pMV262-atpC in solid and 
liquid media. Growth curve experiments were carried out three times independently. Mean values 
with standard deviations are shown. 
 
 
Colony morphology and growth pattern of this strain were indistinguishable 
from that of the wild type (Fig. 4.7). The colony size and shape in solid media and 
the generation time, time to reach stationary phase were the same as that of wild 
type M. smegmatis. These results implied that over-expression of the wild-type ε 















































Fig. 4.8: BDQ susceptibility – Dose response curves of wildtype M. smegmatis and its genetic 
derivative in broth dilution method. ‘wt’: wild type M. smegmatis; ‘W16A’: M. smegmatis 
atpC
W16A
, wt overexpr atpC’: wild type M. smegmatis overexpressing wild type ε protein via 
introduction of pMV262-atpC. The experiments were carried out three times independently. Mean 
values with standard deviations are shown. 
 
If the drug indeed inhibits F-ATP synthase in intact bacteria by binding to the 
 
ε subunit of the enzyme, increasing the intracellular target concentration, i.e. 
overexpression of the wild type ε subunit in wild type bacteria, is expected to 
result in reduced sensitivity, i.e. increased resistance to BDQ. Fig. 4.8 shows that 
























4.5 Intracellular ATP concentration 
 
After observing the phenotype of BDQ hyper-sensitivity, it would be interesting 
 
to address whether the intracellular ATP concentration is altered in the M. smegmatis 
atpC
W16A
 strain. ATP content was measured and compared with M. smegmatis wild 
type as described earlier in chapter 2. However, the ATP content was found to be 4.6 
± 0.5 x 10
-18
 CFU/ml for wild type M. smegmatis culture and 5.2 ± 0.5 x 10
-18
 
CFU/ml for M. smegmatis atpC
W16A
, showing that the intracellular ATP 




Table 4.2: Intracellular ATP concentration comparison 
 
 M. smegmatis M. smegmatis atpC
W16A 
Intracellular ATP (CFU/ml) (CFU/ml) 
concentration 
  
4.6 ± 0.5 x 10
-18 
5.2 ± 0.5 x 10-
18 
 



























According to the binding model, another amino acid residue which was within 
 
5 Å of BDQ molecule, and therefore might give necessary polar interaction to the 
 
drug, is R37. So, to understand whether this prediction about the role of R37 






















Fig. 4.9: 1% DNA agarose gel of colony PCR to screen for M. smegmatis atpC recombinants 
containing point mutation R37G. In this gel picture, only one colony (no. 4) shows bright band 
implying it has mutant DNA while the remaining don’t. Amplicon size ~600 bp. L is the 1kb ladder 
 
In this case also, the mixed DNA problem persisted (black arrow in Fig. 4.10-
B) in the initial phase of screening, which was again overcome by multiple rounds 
















For this mutant, in the 14
th
 round of passage, pure mutant R37G DNA was 
obtained without any mixing with the wildtype. This will be clear from the 











































































Fig. 4.10: DNA sequence chromatograms showing A) Wildtype M. smegmatis with arginine 
codon number 37 (CCG) B) Mutant codon glycine (CCC) being introduced at position 37 but with 
remnant wildtype DNA (black arrow) C) Purely mutant codon (CCC) thus generating M. 
smegmatis atpC
R37G
 in which arginine is replaced by glycine 
 
Once the sequence of the mutant strain was confirmed, the recombineering 
plasmid was removed and further microbiological characterization experiments of 
this strain followed. 
 
 
4.7 Microbiological characterization of the mutant M. smegmatis atpC
R37G 
 
4.7.1 Growth comparison on solid agar medium 
 
The colony morphology of the mutant M. smegmatis atpC
R37G
 in solid agar 






Inspirational quote- “The greatest challenge to any thinker is stating 
 































Fig. 4.11: Growth of wild type M. smegmatis and mutant R37G on solid medium. Colonies are 
shown after 4 days of incubation. ‘wt’: wildtype M. smegmatis ‘R37G’; M. smegmatis atpCR37G, 
 
As evident from the Fig. 4.11, the colony morphology of M. smegmatis 
atpC
R37G
 mutant is indistinguishable from that of the wild type. 
 
4.7.2 Growth comparison in liquid medium 
 
The mutant strain was then subjected to growth curve experiments in broth 
culture to see if the mutation R37G affected the growth pattern of the resultant 
mutant. It was observed that the generation time and time to reach the stationary 
phase remained the same as that of the wild type). 
 
The growth in solid and liquid media, being indistinguishable from the wild 













































Fig. 4.12: Growth of wild type M. smegmatis and its genetic derivative in liquid medium. ‘wt’: 
wildtype M. smegmatis; ‘R37G’: M. smegmatis atpCR37G. The experiments were carried out three 
times independently. Mean values with standard deviations are shown. 
 
 
4.7.3 BDQ susceptibility comparison 
 
After having confirmed one of the predictions from the biophysical in vitro 
modelling study [89], that W16A amino acid residue of the epsilon subunit is 
indeed involved in the BDQ binding, next question was to determine if the amino 
acid residue R37 is involved in the same as well. To answer this question, BDQ 
susceptibility of the bacterium i.e. growth inhibition dose response curves were 
determined. It was predicted that this amino acid (R37) being within 5 Å of BDQ 










































Figure 4.13: BDQ susceptibility – Dose response curves of wild type M. smegmatis and its genetic 




Interestingly, unlike in the case of W16A mutation, as it is evident from figure 
4.13, the mutation R37G did not result in any shift of MIC50 of M. smegmatis 
atpC
R37G
 from that of wild type M. smegmatis. 
There are several possible explanations why changing arginine 37 in the ε 
subunit had no effect on the susceptibility of BDQ. First, the proposed binding 
model suggesting an interaction with arginine 37 is not correct and may require 
modification. Alternatively, the proposed binding model may be correct; however, 
the contribution of arginine 37 to BDQ binding may not be detectable by genetic 










when interrupted. In general terms, genetic confirmation of a biochemically 





Taken together, in this chapter we observed a very interesting hyper-sensitivity 
phenotype of the W16A mutant. The mutant could be complemented, and also 
additionally supported by an overexpression experiment. From these above findings, 
for the first time, we can conclude that the BDQ drug, in addition to the oligomeric c-
ring, also interacts with the epsilon subunit at specific residues. The tryptophan-16 
clearly plays an important role in the BDQ-ε interaction. 
 
An interesting follow-up of this study would be the spontaneous resistant 





strains. If whole genome sequencing of such mutants reveal 
mutations in epsilon subunit, that would indeed be a giant’s leap in this field. A 
comprehensive mutational analysis in which all proposed interacting amino acid 


















































Role of the c-terminal residues of Epsilon 
subunit of mycobacterial ATP synthase in 













Findings from this chapter have been included in the following manuscript: 
 
Shin Joon, Priya Ragunathan, Lavanya Sundararaman, Wilson Nartey, Subhashri 
Kundu, Malathy Sony Subramanian Manimekalai, Nebojša Bogdanović, Thomas 
Dick and Gerhard Grüber. “NMR solution structure of subunit ε of the  
Mycobacterium tuberculosis F-ATP synthase and novel aspects of energy 














Although the central objective of this PhD project has been to understand the 
mechanism of action of the BDQ drug, another additional aim is, to understand 
the role of the C-Terminal Domain (CTD) of the Epsilon subunit of the 
mycobacterial ATP synthase complex in ATP synthesis and hydrolysis. In the 
current chapter, the findings from this part of the project shall be discussed. The 
results from these studies finds their relevance when conjugated with the findings 
from the structural studies of our collaborators. 
 
From the recent solution structure of the MTB ε subunit solved by our 
collaborators (unpublished data), it was shown that the MtεCTD is oriented in the 
opposite direction compared to most other bacilli like E. coli εCTD. Importantly, 
amino acids A119 and I120 of the very C-terminus are oriented towards the NTD, 
forming a domain-domain interface between the NTD and CTD via the NTD 
residues D47, D48, A49 and A64. The NTD on the other hand has a direct contact 
with the helix-loop-helix region of ion-pumping c-ring 
 
These interactions could influence the ATP synthesis and hydrolysis output of the 
enzyme complex. Now that we know that, BDQ also interacts with the ε subunit, it 
would be interesting to understand the role of CTD residues in ATP synthesis and 
hydrolysis, in context of search for new TB drug targets. So, to find out the role, one 
needs to determine how these processes get affected when these residues are absent. 











5.1 Constructing the ∆ε102-121 and ∆ε120-121 mutants 
 
To understand the role of the C-terminal residues we decided to create 
mutants by inserting a STOP codon after the 101
st
 (for ∆ε102-121) and 120th (for 
∆ε120-121) codon in the atpC gene (Fig. 5.1). Recombineering technique was 
employed as described previously in chapter 2 to do a point mutation at those 
specific residues converting them into the STOP codon (TAG) and create the two 
M. smegmatis mutants: 
▪ ∆ε102-121 - without the c-terminal helix
▪ ∆ε120-121 - without the last Aspartic acid
 












Fig. 5.1: Amino acid residues and their respective codons of the CTD of the ε subunit of the 
 






The point mutations were detected by PCR, using screening primers which 
would anneal only with the mutants and not with the wild type (Fig. 5.2). As 

















































Fig. 5.2: 1% DNA agarose gel of colony PCR to screen for M. smegmatis atpC recombinants 
containing point mutation GAC 

TAG i.e a STOP codon for ∆ε102-121 (top) and ∆ε120-121 
(below). In these gel pictures, colony no. 7 (above) and colony no. 7, 10, 14 (below) shows bright 





After an  initial  round of  mutant  screening,  these  colonies were further 
 

































































Fig. 5.3: DNA sequence chromatograms showing the point mutations GAC 

TAG i.e a STOP codon 
for ∆ε102-121 (top) and ∆ε120-121 (below) thus generating the two different strains ∆ε102- 
 












generating the chromatograms, the peaks are not very isolated in the 2
nd
  figure, despite several 
 
attempts. However, our purpose of confirming the point mutation was solved} 
 
 





5.2 Microbiological characterization of ∆ε102-121 and ∆ε120-121 mutants. 
 
5.2.1 Growth pattern in liquid medium. 
 
It was important to determine whether the insertion of STOP codons in these 
mutants and thereby truncating parts of the CTD of the epsilon subunit of the 
























Fig.5.4: Growth of wild type M. smegmatis and the ∆ε102-121 and ∆ε120-121 mutants in liquid 
medium. The experiments were carried out three times independently. Mean values with standard 
















As evident from Fig. 5.4, no significant differences could be observed 




5.2.2 Growth in solid medium. 
 
To determine if the colony morphology of these mutants were different from 












Fig. 5.5: Growth of wild type M. smegmatis and mutants ∆ε102-121 and ∆ε120-121 on solid 
 
medium. Colonies are shown after 4 days of incubation. 
 
 
Having seen no differences in the colony morphologies (Fig. 5.5), it was 
 





5.3 Biochemical characterization of the ∆ε102-121 and ∆ε120-121 mutants 
 
Since the main objective of this part of the project was to see if the amino acid 
 
residues of the CTD of ε subunit had any role in the ATP synthesis and hydrolysis 
of the enzyme complex, next, we performed the biochemical assays. This part of 









all the biochemical assays, inverted membrane vesicles from two independent 
batches of each strain were prepared and tested separately (one Dr. Priya 
Ragunathan and the other by myself). The results shown below are the mean 































Fig. 5.6 ATP synthesis measurement of IMVs of wild type M. smegmatis and mutants ∆ε102-121 




ATP synthesis activities of the wild type, the Δε102-121 and Δε120-121 mutant 











49% decrease in ATP synthesis activity when compared to the wt IMVs. The 
mutant Δε120-121 showed 65% drop in ATP synthesis in comparison to wt 
thereby demonstrating a decrease in ATP synthesis activity for both mutant 
enzymes. This implies that the CTD residues, plays an important role in ATP 
synthesis, due to which their absence in the mutants causes a significant drop in 
ATP level compared to the wild type. 
 
 























Fig. 5.7 Specific ATP hydrolysis activity of IMVs of wild type M. smegmatis and mutants ∆ε102- 
 
121 and ∆ε120-121. Values are the mean of six determinations with two different IMV batches of 
wt and mutants. 
 
 
As demonstrated in the above figure, IMVs of wild type (wt) M. smegmatis 
 













confirming the recent results which demonstrated that M. smegmatis, although at 
a relatively low level, hydrolyses ATP [47]. In contrast, when IMVs containing 
the F-ATP synthase mutant Δε102-121 were used, an ATPase activity of 42.4 ± 
1.1 nmol min-1 (mg total protein)-1 was observed. Thus, deletion of the C-terminal 
helix of subunit ε caused a 16% increase in ATP hydrolysis activity, which 
suggests that the C-terminal helix of subunit ε in the wt enzyme decreases ATP 
hydrolysis activity. To determine the significance of the last residue D121 of C-
terminal helix of subunit ε, the ATP hydrolysis activity of IMVs of the Δε120-121 
mutant was measured and found to be 41 ± 1.5 nmol min-1 (mg total protein)-1 
(i.e. a 13% increase in ATP hydrolysis activity compared to the wt). These results 
suggest that the C-terminal helix within the specific mycobacterial C-terminal 






As evident from the results from the biochemical assays, the CTD of the ε 
 
subunit must have a significant role in the overall ATP synthesis activity. The 
ATP hydrolysis results also suggest that the CTD residues are responsible for 
suppressing of ATP hydrolysis, preventing excess ATP consumption. These 
results are also in agreement with the trend observed in the biochemical assays 













Importantly, stimulation of latent ATP hydrolysis activity will lead to 
depleted cellular ATP levels during dormancy and decrease the bacteria’s 
viability. 
 
Compounds that can specifically relieve the blockage of ATP hydrolysis, by 
targeting the CTD of ε subunit may thus be potential drug candidates. 
 
However more detailed study in this area, like creating similar truncation 
mutants in the NTD and helix-loop-helix region of c-subunit and determining 
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Tuberculosis is the leading cause of mortality from any infectious diseases, 
second after HIV-AIDS. More than one-third of the current human population is 
infected with the bacteria Mycobacterium tuberculosis, which is a difficult 
pathogen to combat with. Recent emergence of the drug-resistant strains (Multi-
drug-resistant and Extensively-drug-resistant strains), and the complications 
arising due to co-infection with HIV, have worsened the global scenario of TB. 
We are in urgent need for a new TB drug with a novel mechanism of action.  
After a long gap of almost 40 years in the TB drug discovery pipeline, in the 
last decade we saw the discovery of a new TB drug, Bedaquiline which had a 
novel target – F1Fo ATP synthase of mycobacteria. The discovery of BDQ 
brought a new ray of hope for the treatment of MDR TB. It was reported to be 
highly potent against both drug-sensitive and drug-resistant strains of MTB with a 
MIC of 0.002-0.06 μg/ ml [54]. Not only that, it was found to be active against 
both the replicating and the non-replicating stages of mycobacteria (non-
replicating stages of the bacteria are responsible for causing latent TB). Pre-
clinical studies showed that treatment with BDQ regimen for four months was 
equally effective as the treatment with standard regimen for six months.  
But just like the saying goes, ‘every rose has its thorns’, so does Bedaquiline. 
Despite having all these attractive anti-mycobacterial properties, there are a 
considerable number of obstacles which need to be overcome, before BDQ 
emerges as the most promising drug for TB. The most important obstacles are the 
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adverse effects associated with the drug. It has been reported that BDQ disturb 
heart and liver functions [54]. Prolongation of QT interval, hepatotoxicity, drug 
interactions with CYP3A4 inducers and inhibitors were observed in patients after 
this drug intake [73]. So, this drug was granted an ‘accelerated approval’ as a part 
of combination therapy for MDR-TB patients, only when all other alternative 
drug options failed. 
So, the question is, can this obstacle be overcome? The answer to the question 
could be lying in the mechanism of action of the drug. As reviewed before, most 
of the studies so far regarding the mechanism of action of BDQ, have concluded 
that the membrane-embedded c-ring of the mycobacterial ATP synthase is the 
target of this drug. Therefore, to reach the target protein, BDQ would have to 
dissolve through the membrane. And to do that, the drug should be highly 
lipophilic in nature. High lipophilicity of a compound is associated with high 
clogP value (BDQ has clogP value of 7.31), which results in increased drug-
related-toxicity, which could be the reason behind some of the adverse effects of 
BDQ.  
If we can find a new target of BDQ within the ATP synthase enzyme 
complex, which is not located in the membrane region, unlike the c-subunit, that 
could reveal new opportunities in the field of TB drug discovery. In addition to 
that, due to persisting problem of emergence of drug resistance, new drug-target-
finding studies are always encouraged. So, we were interested to explore the 
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possible drug targets in the epsilon subunit of the same enzyme. That exactly is 
where we achieved the most interesting finding of this project. 
Our collaborators recently showed through structural studies (NMR 
spectroscopy, CD spectroscopy and Tryptophan fluorescence spectroscopy) that 
the drug also binds to the epsilon subunit at specific amino acid residues besides 
binding to the already known c-subunit. We wanted to confirm this prediction 
made from structural studies, in intact mycobacterial cells employing genetics. 
Using Recombineering (conditions were optimized as described in chapter 3), 
we created two unique mutations W16A and R37G in the essential atpC gene 
coding for the epsilon subunit of M. smegmatis. Interestingly out of these two, the 
mutation W16A caused 5-fold hyper-sensitivity to the BDQ drug. This finding 
could be confirmed with complementation experiments. Further, as an additional 
line of evidence, we also performed over-expression experiment which 
strengthened our previous finding. 
The hyper-susceptibility phenotype could be possibly due to the replacement 
of a bulkier amino acid tryptophan with a smaller alanine, thereby creating more 
space and a stronger binding. Our data suggest that, as predicted from the 
structural studies, the drug indeed interacts with the ε subunit and that this binding 
occurs close to tryptophan 16 of the protein. These findings for the first time 
provides genetic evidence that the new TB drug BDQ inhibits mycobacterial F-
ATP synthase via a novel second mechanism involving the enzyme’s ε subunit in 
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addition to binding to its c subunit. This information is immensely important and 
useful for the discovery of the next generation of diarylquinolines. 
An important follow-up study in this part of the project is to look for Epsilon 
subunit mutations in spontaneous resistance mutants generated either from wild-
type M. smegmatis or the M. smegmatisI66M (i.e with the c subunit mutation in 
background). If mutations are indeed found in the atpC gene (coding for epsilon 
subunit) in such spontaneous resistant mutants, that would be the final cherry on 
the top.  This follow-up study is currently undertaken by a new PhD student in our 
lab. 
The epsilon subunit (being part of the central stalk) is known to play pivotal 
role in coupling the functions of the two domains- ion-pumping in Fo and ATP 
synthesis in F1. However, the role of the C-terminal domain of this subunit which 
exists in two different conformations – compact and extended, in ATP synthesis 
and hydrolysis is not yet known. From the findings of the first part of the project, 
now we know that the epsilon subunit could be an interesting new target for new 
generations of diarylquinolines. That triggered us to explore in more details 
functions of its CTD. We created two point mutations in atpC gene where the ε-
CTD was truncated to various extents. Biochemical assays performed using these 
mutants, clearly indicated that the CTD residues are crucial in both ATP synthesis 
and suppression of ATP hydrolysis, and could therefore be novel targets for drugs 
targeting mycobacterial energy metabolism. Parallelly, structural studies were 
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also being performed by our collaborators (unpublished data) which strengthens 
our findings from this part of the project. 
Taken together, this PhD project opened a new door by providing valuable 
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